A Phase 1/2 Study to Evaluate MEDI4736
Advanced Solid Tumors
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Treatment of nonmuscle-invasive bladder cancers (Ta, Tis, T1) is based on risk stratification. Essentially all patients are initially treated with transurethral resection (TUR) of the bladder tumor, followed by a single immediate instillation of intravesical chemotherapy (mitomycin is typically used in the United States).[1-7]
Subsequent therapy is based on risk and typically consists of one of the following:[6-9]
Surveillance for relapse or recurrence (typically used for tumors with low risk of recurrence or progression).
A minimum of 1 year of intravesical treatments with bacillus Calmette-Guérin (BCG) plus surveillance for relapse (typically used for tumors at intermediate or high risk of progression to muscle-invasive disease).
Additional intravesical chemotherapy (typically used for tumors with a high risk of recurrence but low risk of progression to muscle-invasive disease).
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Standard treatment for patients with muscle-invasive bladder cancers whose goal is cure is either neoadjuvant multiagent cisplatin–based chemotherapy followed by radical cystectomy and urinary diversion or radiation therapy with concomitant chemotherapy.[10-13] Other treatment approaches include:
Radical cystectomy followed by multiagent cisplatin–based chemotherapy.
Radiation therapy without concomitant chemotherapy.[17]
Sources: 17
Partial cystectomy with or without perioperative chemotherapy.[18]
Sources: 18
Many patients newly diagnosed with bladder cancer are candidates for participation in clinical trials.
Reconstructive techniques that fashion low-pressure storage reservoirs from the reconfigured small and large bowel eliminate the need for external drainage devices and, in many patients, allow voiding per urethra. These techniques are designed to improve the quality of life for patients who require cystectomy.[19]
Sources: 19
| Stage (TNM Staging Criteria) | Treatment Options | |
|---|---|---|
| BCG = bacillus Calmette-Guérin; EBRT = external-beam radiation therapy; TNM = T, size of tumor and any spread of cancer into nearby tissue; N, spread of cancer to nearby lymph nodes; M, metastasis or spread of cancer to other parts of body; TUR = transurethral resection. | ||
| Stage 0 Bladder Cancer | TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy | |
| TUR with fulguration | ||
| TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by periodic intravesical instillations of BCG | ||
| TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by intravesical chemotherapy | ||
| Segmental cystectomy (rarely indicated) | ||
| Radical cystectomy (in rare, highly selected patients with extensive or refractory superficial high-grade tumors) | ||
| Stage I Bladder Cancer | TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy | |
| TUR with fulguration | ||
| TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by periodic intravesical instillations of BCG | ||
| TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by intravesical chemotherapy | ||
| Segmental cystectomy (rarely indicated) | ||
| Radical cystectomy in selected patients with extensive or refractory superficial tumors | ||
| Stages II and III Bladder Cancer | Radical cystectomy | |
| Neoadjuvant chemoimmunotherapy followed by radical cystectomy followed by adjuvant immunotherapy | ||
| Neoadjuvant combination chemotherapy followed by radical cystectomy | ||
| Radical cystectomy followed by adjuvant chemotherapy or immunotherapy | ||
| EBRT with or without concomitant chemotherapy | ||
| Segmental cystectomy (in selected patients) | ||
| TUR with fulguration (in selected patients) | ||
| Stage IV Bladder Cancer | T4b, N0, M0 | Enfortumab vedotin plus pembrolizumab |
| Chemotherapy plus immunotherapy | ||
| Chemotherapy alone | ||
| Systemic therapy followed by radical cystectomy | ||
| EBRT with or without concomitant chemotherapy | ||
| Urinary diversion or cystectomy for palliation | ||
| Any T, any N, M1 | Enfortumab vedotin plus pembrolizumab | |
| Chemotherapy plus immunotherapy | ||
| Chemotherapy alone or as an adjunct to local treatment | ||
| Immunotherapy | ||
| EBRT for palliation | ||
| Urinary diversion or cystectomy for palliation | ||
| Other chemotherapy agents with activity in metastatic bladder cancer, such as paclitaxel, docetaxel, ifosfamide, gallium nitrate, and pemetrexed (under clinical evaluation) | ||
| Clinical trials | ||
| Recurrent Bladder Cancer | Combination chemotherapy | |
| Immunotherapy | ||
| Targeted therapy | ||
| Surgery for new superficial or localized tumors | ||
| Palliative therapy | ||
| Clinical trials | ||
Sources: TNM Staging Criteria · TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy · TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by periodic intravesical instillations of BCG · Segmental cystectomy · Radical cystectomy · TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy · TUR with fulguration · TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by periodic intravesical instillations of BCG · TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by intravesical chemotherapy · Segmental cystectomy · Radical cystectomy · Radical cystectomy · Neoadjuvant chemoimmunotherapy followed by radical cystectomy followed by adjuvant immunotherapy · Neoadjuvant combination chemotherapy followed by radical cystectomy · Radical cystectomy followed by adjuvant chemotherapy or immunotherapy · EBRT with or without concomitant chemotherapy · Segmental cystectomy · TUR with fulguration · Enfortumab vedotin plus pembrolizumab · Chemotherapy plus immunotherapy · Chemotherapy alone · EBRT with or without concomitant chemotherapy · Urinary diversion or cystectomy · Enfortumab vedotin plus pembrolizumab · Chemotherapy plus immunotherapy · Chemotherapy alone or as an adjunct to local treatment · Immunotherapy · EBRT · Urinary diversion or cystectomy · Combination chemotherapy · Immunotherapy · Targeted therapy · Surgery · Palliative therapy · Clinical trials
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[20,21] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[20-22] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[23-25] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[26] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[27]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Patients with stage 0 bladder tumors can be cured by a variety of treatments, even though the tendency for new tumor formation is high. In a series of patients with Ta or T1 tumors who were followed for a minimum of 20 years or until death, the risk of bladder cancer recurrence after initial resection was 80%.[1] Of greater concern than recurrence is the risk of progression to muscle-invasive, locally-advanced, or metastatic bladder cancer. While progression is rare for patients with low-grade tumors, it is common among patients with high-grade cancers.
Sources: stage 0 bladder tumors · 1
One series of 125 patients with TaG3 cancers followed for 15 to 20 years reported that 39% progressed to more advanced-stage disease while 26% died of urothelial cancer. In comparison, among 23 patients with TaG1 tumors, none died and 5% progressed.[2] Risk factors for recurrence and progression include:[2-6]
High-grade disease.
Presence of carcinoma in situ.
Tumor larger than 3 cm.
Multiple tumors.
History of prior bladder cancer.
Treatment options for stage 0 bladder cancer include:
Transurethral resection (TUR) with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy.
TUR with fulguration.
TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by periodic intravesical instillations of bacillus Calmette-Guérin (BCG).
TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by intravesical chemotherapy.
Segmental cystectomy (rarely indicated).
Sources: Segmental cystectomy
Radical cystectomy (in rare, highly selected patients with extensive or refractory superficial high-grade tumors).
Sources: Radical cystectomy
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
TUR and fulguration are the most common and conservative forms of management. Careful surveillance of subsequent bladder tumor progression is important. Because most bladder cancers recur after TUR, one immediate intravesical instillation of chemotherapy is often given after TUR. Numerous randomized controlled trials have evaluated this practice, and a meta-analysis of seven trials reported that a single intravesical treatment with chemotherapy reduced the odds of recurrence by 39% (odds ratio [OR], 0.61; P < .0001).[7,8] However, although a single instillation of chemotherapy lowers the relapse rate in patients with multiple tumors, most still relapse. Such treatment is insufficient by itself for these patients.
One retrospective series addressed the value of performing a second TUR within 2 to 6 weeks of the first TUR.[9][Level of evidence C3] A second TUR performed on 38 patients with Tis or Ta disease revealed that nine patients (24%) had lamina propria invasion (T1) and three patients (8%) had muscle invasion (T2).[9]
Sources: 9 · Level of evidence C3 · 9
Such information may change the definitive management options in these individuals. Patients with extensive multifocal recurrent disease and/or other unfavorable prognostic features require more aggressive forms of treatment.
Evidence (TUR with fulguration followed by immediate postoperative instillation of intravesical chemotherapy):
A 2004 meta-analysis of seven randomized controlled trials (1,476 patients with stage Ta or stage T1 bladder cancer) compared TUR alone with TUR followed by a single immediate intravesical instillation of chemotherapy.[7]
Sources: 7
A 2004 meta-analysis of seven randomized controlled trials (1,476 patients with stage Ta or stage T1 bladder cancer) compared TUR alone with TUR followed by a single immediate intravesical instillation of chemotherapy.[7]
The relapse rate was 48% for patients who received TUR alone and 37% for patients who received TUR plus intravesical chemotherapy (OR, 0.61; P < .0001). The risk of recurrence declined for patients with single (OR, 0.61) or multiple (OR, 0.44) tumors, but 65% of those with multiple tumors relapsed despite intravesical chemotherapy.
Agents studied included epirubicin, mitomycin (MMC), thiotepa, and pirarubicin.
A subsequent multicenter randomized controlled trial confirmed the reduction in risk of recurrence. A study that included 404 patients reported a relapse rate of 51% for patients who received epirubicin immediately after TUR and 63% for patients who received placebo immediately after TUR (P = .04). However, only small recurrences were prevented in this study, drawing into question the magnitude of benefit.[10]
Sources: 10
Similarly, another multicenter randomized controlled trial confirmed the reduction in risk of recurrence. One study randomly assigned patients (N = 305) to receive either an instillation of epirubicin or no further treatment after TUR.[8]
Sources: 8
Similarly, another multicenter randomized controlled trial confirmed the reduction in risk of recurrence. One study randomly assigned patients (N = 305) to receive either an instillation of epirubicin or no further treatment after TUR.[8]
The relapse rates were 62% for patients who received epirubicin and 77% for patients in the control arm (P = .016).
The hazard ratio for recurrence was 0.56 (P = .002) with epirubicin. However, the main benefit was seen in patients at lower risk of relapse. Among patients at intermediate or high risk of relapse, the relapse rates were 81% with epirubicin versus 85% with no further treatment (P = .35).
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Intravesical BCG is the treatment of choice for reducing the risk of cancer progression and is mainly used for cancers with an intermediate or high risk of progressing.[6,11-13] An individual patient meta-analysis of randomized trials compared intravesical BCG with intravesical MMC. The meta-analysis reported that there was a 32% reduction in risk of recurrence with BCG but only when the BCG treatment included a maintenance phase whereby BCG was given periodically for at least 1 year (typically an induction phase of six weekly treatments followed by three weekly treatments every 3 months).[12] Intravesical chemotherapy is tolerated better than intravesical BCG.[14-18] Although BCG may not prolong overall survival for Tis disease, it appears to afford complete response rates of about 70%, thereby decreasing the need for salvage cystectomy.[17] Studies show that intravesical BCG delays tumor recurrence and tumor progression.[18,19]
Intravesical therapy with thiotepa, MMC, doxorubicin, or BCG is most often used in patients with multiple tumors or recurrent tumors or as a prophylactic measure in high-risk patients after TUR.[20-22]
Evidence (TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by periodic intravesical instillations of BCG):
Intravesical chemotherapy
Three meta-analyses of randomized controlled trials that compared TUR alone with TUR followed by intravesical chemotherapy reported that adjuvant therapy was associated with a statistically significant increase in time to recurrence.[23-25] No advantage has been shown with respect to survival or prevention of progression to invasive disease or metastases.
Intravesical BCG with maintenance BCG treatments
An individual patient meta-analysis of nine randomized trials (2,820 patients with Ta or T1 bladder cancer) that compared intravesical BCG with intravesical MMC was published.[12]
Sources: 12
An individual patient meta-analysis of nine randomized trials (2,820 patients with Ta or T1 bladder cancer) that compared intravesical BCG with intravesical MMC was published.[12]
Among trials in which the BCG treatment included a maintenance component, there was a 32% reduction in risk of recurrence (P < .0001) compared with MMC. BCG was associated with a 28% increase in the risk of recurrence when there was no maintenance BCG administered compared with MMC.
There were no differences in progression or death.[12]
Sources: 12
A meta-analysis of nine randomized controlled trials (2,410 patients) that compared intravesical BCG with MMC was published.[26]
Sources: 26
A meta-analysis of nine randomized controlled trials (2,410 patients) that compared intravesical BCG with MMC was published.[26]
Progression was observed in 7.67% of the patients who received BCG and 9.44% of patients who received MMC at a median follow-up of 26 months (P = .08).
When the analysis was limited to trials in which the BCG arm included a maintenance component, the progression rate was significantly lower in the patients who received BCG (OR, 0.66; 95% confidence interval, 0.47–0.94; P = .02).
A meta-analysis of the published results of nine randomized controlled trials that compared intravesical BCG with intravesical chemotherapy in 700 patients with carcinoma in situ of the bladder was published.[11]
Sources: 11
A meta-analysis of the published results of nine randomized controlled trials that compared intravesical BCG with intravesical chemotherapy in 700 patients with carcinoma in situ of the bladder was published.[11]
With a median follow-up of 3.6 years, 47% of the BCG group had no evidence of disease and 26% of the chemotherapy group had no evidence of disease.
BCG was superior to MMC at preventing recurrence only when maintenance BCG was part of the treatment.
A controlled trial evaluated 384 patients randomly assigned to induction intravesical BCG or induction intravesical BCG followed by maintenance intravesical BCG.[27]
Sources: 27
A controlled trial evaluated 384 patients randomly assigned to induction intravesical BCG or induction intravesical BCG followed by maintenance intravesical BCG.[27]
The median recurrence-free survival was 36 months without maintenance BCG and 77 months in the maintenance arm (P < .0001). The risk of disease worsening (progression to T2 or greater disease, use of cystectomy, systemic chemotherapy, or radiation therapy) was greater in the induction arm than in the maintenance arm (P = .04).
The 5-year overall survival rate was 78% in the induction arm versus 83% in the maintenance arm, but this difference was not statistically significant.
BCG is associated with a risk of significant toxicity, including rare deaths from BCG sepsis. Compared with MMC, BCG produces more local toxicity (44% with BCG vs. 30% with MMC) and systemic side effects (19% with BCG vs. 12% with MMC). Because of concerns about side effects and toxicity, BCG is not generally used for patients with a low risk of progression to advanced-stage disease.[6,26]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Segmental cystectomy is rarely indicated.[22] It is indicated for relatively few patients because of the tendency of bladder cancer to involve multiple regions of the bladder mucosa and to occur in areas that cannot be segmentally resected. Moreover, cystectomy (whether segmental or radical) is generally not indicated for T0 bladder cancer (see radical cystectomy below).[28,29]
Sources: 22 · radical cystectomy · 28 · 29
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Radical cystectomy is used in selected patients with extensive or refractory superficial tumors,[2,30,31] based on reports that up to 20% of patients with Tis will die of bladder cancer. However, cystectomy (whether segmental or radical) is generally not indicated for patients with Ta or Tis bladder cancer. Patients at high risk of progression, typically those with recurrent high-grade tumors with carcinoma in situ after intravesical therapy with BCG, should consider radical cystectomy.[32-35]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Patients with stage I bladder tumors are unlikely to die of bladder cancer, but the tendency for new tumor formation is high. In a series of patients with Ta or T1 tumors who were followed for a minimum of 20 years or until death, the risk of bladder recurrence after initial resection was 80%.[1] Of greater concern than recurrence is the risk of progression to muscle-invasive, locally-advanced, or metastatic bladder cancer. While progression is rare for low-grade tumors, it is common among high-grade cancers.
Sources: stage I bladder tumors · 1
One series of 125 patients with TaG3 cancers followed for 15 to 20 years reported that 39% progressed to more advanced stage disease, while 26% died of urothelial cancer. In comparison, among 23 patients with TaG1 tumors, none died and 5% progressed.[2] Risk factors for recurrence and progression include:[2-6]
High-grade disease.
Presence of carcinoma in situ.
Tumor larger than 3 cm.
Multiple tumors.
History of prior bladder cancer.
Treatment options for stage I bladder cancer include:
Transurethral resection (TUR) with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy.
TUR with fulguration.
Sources: TUR with fulguration
TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by periodic intravesical instillations of bacillus Calmette-Guérin (BCG).
TUR with fulguration followed by an immediate postoperative instillation of intravesical chemotherapy followed by intravesical chemotherapy.
Segmental cystectomy (rarely indicated).
Sources: Segmental cystectomy
Radical cystectomy (in selected patients with extensive or refractory superficial tumors).
Sources: Radical cystectomy
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
TUR and fulguration are the most common and conservative forms of management. Careful surveillance of subsequent bladder tumor progression is important. Because most bladder cancers recur after TUR, one immediate intravesical instillation of chemotherapy after TUR is widely used. Numerous randomized controlled trials have evaluated this practice, and a meta-analysis of seven trials reported that a single intravesical treatment with chemotherapy reduced the odds of recurrence by 39% (odds ratio [OR], 0.61; P < .0001).[7,8]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Staging a bladder cancer via TUR is based on the extent of invasion. To assess whether cancer has invaded the muscle, muscularis propria must be present in the resected tissue. While a repeat TUR is generally considered mandatory for T1 and high-grade noninvasive bladder cancers if no muscularis propria is present in the resected tissue from the first TUR, many experts recommend that a second TUR be routinely performed within 2 to 6 weeks of the first TUR to confirm staging and achieve a more complete resection. The rationale for this derives from numerous findings, including:
The risk of local recurrence after TUR is high.
Residual cancer is often found when a repeat TUR is performed.
More-advanced–stage cancer is sometimes found with repeat TUR.
Patients undergoing radical cystectomy for nonmuscle-invasive bladder cancer are often found to have T2 or greater disease when the cystectomy specimen is examined.
A substantial number of patients with high-grade nonmuscle-invasive bladder cancer subsequently die of their disease.
Evidence (routine repeat TUR):
A review of more than 2,400 patients from over 60 different institutions reported a 3-month recurrence rate of roughly 14% to 20% after TUR, while a literature review reported that up to 10% of patients who underwent a second TUR for Ta to T1 cancer were upstaged to T2.[9] The likelihood of being upstaged to T2 is much higher when no muscularis propria is present in the initial TUR tissue.[10]
One retrospective series of 38 patients with Tis or Ta disease who underwent a second TUR found that nine patients (24%) had lamina propria invasion (T1) and three patients (8%) had muscle invasion (T2).[11]
Sources: 11
A subsequent study from a different institution reported that among 214 patients with Ta to T1 cancers who underwent a second TUR, 27% of Ta and 37% of T1 patients had residual cancer detected.[12]
Sources: 12
A review of other published papers reported that residual tumor was present in 27% to 62% of cases, and muscle-invasive disease was discovered in 1% to 10% of case series with at least 50 patients.[10]
Sources: 10
Repeat TUR has not been shown to reduce relapse rates or prolong survival, but there is a clear rationale for seeking accurate staging information on which to base treatment decisions. Such information may change the definitive management options for patients and identify patients who are more likely to benefit from more aggressive treatment.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Intravesical BCG is the treatment of choice for reducing the risk of cancer progression and is mainly used for cancers with an intermediate or high risk of progressing.[6,13-15] An individual patient meta-analysis of randomized trials that compared intravesical BCG with intravesical mitomycin (MMC) reported that there was a 32% reduction in risk of recurrence with BCG but only when the BCG treatment included a maintenance phase whereby BCG was given periodically for at least 1 year (typically an induction phase of six weekly treatments followed by three weekly treatments every 3 months).[14] Intravesical chemotherapy is tolerated better than intravesical BCG.[16-20] Although BCG may not prolong overall survival for Tis disease, it appears to afford complete response rates of about 70%, thereby decreasing the need for salvage cystectomy.[19] Studies show that intravesical BCG delays tumor recurrence and tumor progression.[20,21]
Evidence (immediate intravesical chemotherapy after transurethral resection):
A 2004 meta-analysis of seven randomized controlled trials (1,476 patients with Ta or T1 bladder cancer) compared TUR alone with TUR followed by a single immediate intravesical instillation of chemotherapy. Agents studied included epirubicin, MMC, thiotepa, and pirarubicin.[7]
Sources: 7
A 2004 meta-analysis of seven randomized controlled trials (1,476 patients with Ta or T1 bladder cancer) compared TUR alone with TUR followed by a single immediate intravesical instillation of chemotherapy. Agents studied included epirubicin, MMC, thiotepa, and pirarubicin.[7]
The relapse rates were 48% for patients who received TUR alone and 37% for patients who received TUR plus intravesical chemotherapy (OR, 0.61; P < .0001). The risk of recurrence declined for patients with single (OR, 0.61) or multiple (OR, 0.44) tumors, but 65% of those with multiple tumors relapsed despite intravesical chemotherapy.
A subsequent multicenter randomized controlled trial confirmed the reduction in risk of recurrence. A study that included 404 patients reported a relapse rate of 51% for patients who received epirubicin immediately after TUR and 63% for patients who received placebo immediately after TUR (P = .04). However, only small recurrences were prevented in this study, drawing into question the magnitude of benefit.[22]
Sources: 22
Similarly, another multicenter randomized controlled trial confirmed the reduction in risk of recurrence. One study randomly assigned patients (N = 305) to receive either an instillation of epirubicin or no further treatment after TUR.[8]
Sources: 8
Similarly, another multicenter randomized controlled trial confirmed the reduction in risk of recurrence. One study randomly assigned patients (N = 305) to receive either an instillation of epirubicin or no further treatment after TUR.[8]
The relapse rates were 62% for patients who received epirubicin and 77% for patients in the control arm (P = .016).
The hazard ratio for recurrence was 0.56 (P = .002) with epirubicin. However, the main benefit was seen in patients at lower risk of relapse. Among patients at intermediate or high risk of relapse, the relapse rates were 81% with epirubicin versus 85% with no further treatment (P = .35).
Evidence (intravesical BCG with maintenance BCG treatments):
An individual patient meta-analysis of nine randomized trials (2,820 patients with Ta or T1 bladder cancer) that compared intravesical BCG with intravesical MMC was published.[14]
Sources: 14
An individual patient meta-analysis of nine randomized trials (2,820 patients with Ta or T1 bladder cancer) that compared intravesical BCG with intravesical MMC was published.[14]
Among trials in which the BCG treatment included a maintenance component, there was a 32% reduction in risk of recurrence (P < .0001) compared with MMC. BCG was associated with a 28% increase in the risk of recurrence when no maintenance BCG was given compared with MMC.
There were no differences in progression or death.
A meta-analysis of nine randomized controlled trials (2,410 patients) that compared intravesical BCG with MMC was published.[23]
Sources: 23
A meta-analysis of nine randomized controlled trials (2,410 patients) that compared intravesical BCG with MMC was published.[23]
Progression was seen in 7.67% of the patients who received BCG and 9.44% of patients who received MMC at a median follow-up of 26 months (P = .08).
When the analysis was limited to trials in which the BCG arm included a maintenance component, the progression rate was significantly lower in the patients who received BCG (OR, 0.66; 95% confidence interval, 0.47–0.94; P = .02).
A meta-analysis of the published results of nine randomized controlled trials that compared intravesical BCG with intravesical chemotherapy in 700 patients with carcinoma in situ of the bladder was published.[13]
Sources: 13
A meta-analysis of the published results of nine randomized controlled trials that compared intravesical BCG with intravesical chemotherapy in 700 patients with carcinoma in situ of the bladder was published.[13]
With a median follow-up of 3.6 years, 47% of the BCG group had no evidence of disease and 26% of the chemotherapy group had no evidence of disease.
In this meta-analysis, BCG was superior to MMC at preventing recurrence only when maintenance BCG was part of the treatment.
A controlled trial evaluated 384 patients randomly assigned to induction intravesical BCG or induction intravesical BCG followed by maintenance intravesical BCG.[24]
Sources: 24
A controlled trial evaluated 384 patients randomly assigned to induction intravesical BCG or induction intravesical BCG followed by maintenance intravesical BCG.[24]
Median recurrence-free survival was 36 months without maintenance BCG and 77 months in the maintenance arm (P < .0001). The risk of disease worsening (progression to T2 or greater disease, use of cystectomy, systemic chemotherapy, or radiation therapy) was greater in the induction arm than in the maintenance arm (P = .04).
The 5-year overall survival rate was 78% in the induction arm versus 83% in the maintenance arm, but this difference was not statistically significant.
BCG is associated with a risk of significant toxicity, including rare deaths from BCG sepsis. Compared with MMC, BCG produces more local toxicity (44% with BCG vs. 30% with MMC) and systemic side effects (19% with BCG vs. 12% with MMC). Because of concerns about side effects and toxicity, BCG is not generally used for patients with a low risk of progression to more-advanced–stage disease.[6,23]
Evidence (two treatment courses of intravesical BCG):
Two nonconsecutive 6-week courses with BCG may be necessary to obtain optimal response.[25] Patients with a T1 tumor at the 3-month evaluation after a 6-week course of BCG and patients with Tis that persists after a second 6-week BCG course have a high likelihood of developing muscle-invasive disease and should be considered for cystectomy.[18,25,26]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Intravesical therapy with thiotepa, MMC, doxorubicin, or BCG is most often used in patients with multiple tumors or recurrent tumors or as a prophylactic measure in high-risk patients after TUR.[27,28]
Evidence (intravesical chemotherapy):
Three meta-analyses of randomized controlled trials that compared TUR alone with TUR followed by intravesical chemotherapy reported that adjuvant therapy was associated with a statistically significant increase in time to recurrence. No advantage has been shown with respect to survival or prevention of progression to invasive disease or metastases.[29-31]
Three meta-analyses of randomized controlled trials that compared TUR alone with TUR followed by intravesical chemotherapy reported that adjuvant therapy was associated with a statistically significant increase in time to recurrence. No advantage has been shown with respect to survival or prevention of progression to invasive disease or metastases.[29-31]
One analysis of eight studies with a combined total of 1,609 patients reported that intravesical chemotherapy reduced the risk of relapse at 1 year by 38% and by as much as 70% at 3 years, depending on which drugs were used.[30]
Sources: 30
Another analysis of 11 studies that enrolled a total of 3,703 patients reported a 44% reduction in 1-year recurrence rates.[30]
Sources: 30
An earlier study of 2,535 patients enrolled in six different randomized controlled trials reported a decreased risk of recurrence but not significant benefit with regard to risk of progression to more-advanced–stage disease or survival.[29]
Sources: 29
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Segmental cystectomy is rarely indicated.[32] It is indicated for relatively few patients because of the tendency of bladder carcinoma to involve multiple regions of the bladder mucosa and to occur in areas that cannot be segmentally resected. Moreover, cystectomy (whether segmental or radical) is generally not indicated for patients with T0 bladder cancer.[33,34]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Radical cystectomy is used in selected patients with extensive or refractory superficial tumors.[35-43] Patients at high risk of progression, typically those with recurrent high-grade tumors with carcinoma in situ after intravesical therapy with BCG, should consider radical cystectomy. Other risk factors include multiple tumors and tumors larger than 3 cm.
Certain patients with nonmuscle-invasive bladder cancer face a substantial risk of progression and death from their cancers.
Evidence (radical cystectomy):
One analysis of 307 patients enrolled in studies of intravesical BCG in the 1980s reported that among 85 patients with T1 recurrence, 60 progressed to at least stage II disease. Five years after T1 recurrence, 71% had progressed and 48% had died of their cancer.[44]
Sources: 44
By comparison, in another cohort of 589 patients treated with BCG between 1992 and 2004, 65 of the 120 patients with T1 recurrence underwent immediate cystectomy. Among all patients with T1 recurrence, 28% progressed to more-advanced–stage disease and 31% died of their cancer. While these data confirm that patients with recurring cancer after intravesical BCG face a substantial risk of dying of their disease, they do not provide strong evidence that immediate cystectomy results in a lower risk of death or progression.[44]
Sources: 44
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Treatment options for stage II bladder cancer and stage III bladder cancer include:
Sources: stage II bladder cancer · stage III bladder cancer
Radical cystectomy.
Sources: Radical cystectomy
Neoadjuvant chemoimmunotherapy followed by radical cystectomy followed by adjuvant immunotherapy.
Sources: Neoadjuvant chemoimmunotherapy followed by radical cystectomy followed by adjuvant immunotherapy
Neoadjuvant combination chemotherapy followed by radical cystectomy.
Sources: Neoadjuvant combination chemotherapy followed by radical cystectomy
Radical cystectomy followed by adjuvant chemotherapy or immunotherapy.
Sources: Radical cystectomy followed by adjuvant chemotherapy or immunotherapy
External-beam radiation therapy (EBRT) with or without concomitant chemotherapy.
Sources: External-beam radiation therapy (EBRT) with or without concomitant chemotherapy
Segmental cystectomy (in selected patients).
Sources: Segmental cystectomy
Transurethral resection (TUR) with fulguration (in selected patients).
The most common treatments for muscle-invasive bladder cancer are radical cystectomy and radiation therapy. There is no strong evidence from randomized controlled trials to determine whether surgery or radiation therapy is more effective. There is strong evidence that both therapies are more effective when combined with chemotherapy. The treatments with the highest levels of evidence supporting their effectiveness are radical cystectomy preceded by multiagent cisplatin-based chemotherapy and radiation therapy with concomitant chemotherapy.
Because bladder cancer commonly recurs with distant metastases, studies have evaluated giving systemic immunotherapy or chemotherapy before or after cystectomy as a means of improving outcomes.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Radical cystectomy is a standard treatment option for stage II and stage III bladder cancer, and its effectiveness at prolonging survival increases if it is preceded by cisplatin-based multiagent chemotherapy.[1-4] Radical cystectomy is accompanied by pelvic lymph node dissection and includes removal of the bladder, perivesical tissues, prostate, and seminal vesicles in men and removal of the uterus, fallopian tubes, ovaries, anterior vaginal wall, and urethra in women.[5-8] Studies of outcomes after radical cystectomy report increased survival in patients who had more, rather than fewer, lymph nodes resected. It is unknown whether this represents a therapeutic benefit of resecting additional nodes or stage migration.[9] There are no randomized controlled trials evaluating the therapeutic benefit of lymph node dissection in this setting.
Radical cystectomy is a major operation with a perioperative mortality rate of 2% to 3% when performed at centers of excellence.[6-8] Postoperative complications include ileus. Most men have erectile dysfunction after radical cystectomy. Sexual dysfunction after this operation is also common in women.[10-12]
One study of 27 women who underwent radical cystectomy reported diminished ability to have orgasm in 45%, decreased lubrication in 41%, decreased sexual desire in 37%, and pain with vaginal intercourse in 22%. Fewer than one-half were able to have successful vaginal intercourse and most reported decreased satisfaction with their sexual lives after surgery.[12] Studies suggest that radical cystectomy with preservation of sexual function can be performed in some men. In addition, new forms of urinary diversion can obviate the need for an external urinary appliance.[13-16]
In a retrospective analysis from a single institution, older patients (≥70 years) in good general health were found to have clinical and functional results after radical cystectomy similar to younger patients.[17]
Sources: 17
After radical cystectomy, however, an approximate 30% to 40% risk of recurrence still exists for patients with muscle-invasive disease, even at centers of excellence.[6-8] The 5-year overall survival (OS) rates range from 50% to 60%, but these rates vary by cancer stage.[4] The addition of preoperative radiation therapy to radical cystectomy did not result in any survival advantage when compared with radical cystectomy alone in a prospective randomized trial.[18]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
In patients eligible for immunotherapy, adding perioperative immunotherapy to standard-of-care cisplatin-based combination chemotherapy before radical cystectomy may further improve survival.
Evidence (neoadjuvant chemoimmunotherapy followed by radical cystectomy followed by adjuvant immunotherapy):
A randomized controlled trial (NIAGARA [NCT03732677]) compared neoadjuvant durvalumab plus gemcitabine and cisplatin followed by radical cystectomy and adjuvant durvalumab (durvalumab arm) with neoadjuvant gemcitabine and cisplatin followed by radical cystectomy (comparison arm). The study included 1,063 patients with clinical stage T2 or higher muscle-invasive bladder cancer. Patients were eligible to receive cisplatin if they had a creatinine clearance of at least 40 mL/min. Four cycles of neoadjuvant durvalumab (1,500 mg) were given every 3 weeks, and up to eight cycles of adjuvant durvalumab (1,500 mg) were given every 4 weeks.[19][Level of evidence A1]
Sources: NIAGARA · 19 · Level of evidence A1
A randomized controlled trial (NIAGARA [NCT03732677]) compared neoadjuvant durvalumab plus gemcitabine and cisplatin followed by radical cystectomy and adjuvant durvalumab (durvalumab arm) with neoadjuvant gemcitabine and cisplatin followed by radical cystectomy (comparison arm). The study included 1,063 patients with clinical stage T2 or higher muscle-invasive bladder cancer. Patients were eligible to receive cisplatin if they had a creatinine clearance of at least 40 mL/min. Four cycles of neoadjuvant durvalumab (1,500 mg) were given every 3 weeks, and up to eight cycles of adjuvant durvalumab (1,500 mg) were given every 4 weeks.[19][Level of evidence A1]
At 24 months, the OS rate was 82.2% (95% confidence interval [CI], 78.7%–85.2%) in the durvalumab arm and 75.2% (95% CI, 71.3%–78.8%) in the comparison arm (hazard ratio [HR], 0.75; 95% CI, 0.59–0.93).
At 24 months, the event-free survival (EFS) rate was 67.8% (95% CI, 63.6%–71.7%) in the durvalumab arm and 59.8% (95% CI, 55.4%–64.0%) in the comparison arm (HR, 0.68; 95% CI, 0.56–0.82).
Grade 3 or higher treatment-related adverse events occurred in 40.6% of patients in the durvalumab arm and 40.9% of patients in the comparison arm.
Radical cystectomy was performed in 88.0% of patients in the durvalumab arm and 83.2% of patients in the comparison arm.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Giving chemotherapy before cystectomy (i.e., neoadjuvant chemotherapy) may be preferable to postoperative treatment because tumor downstaging from chemotherapy may enhance resectability; occult metastatic disease may be treated as early as possible; and chemotherapy may be better tolerated. Currently, the body of evidence supporting preoperative chemotherapy is much stronger than the evidence supporting postoperative chemotherapy.
Evidence (neoadjuvant combination chemotherapy followed by radical cystectomy):
A controlled trial of preoperative chemotherapy conducted by the Medical Research Council and the European Organisation for Research and Treatment of Cancer included 976 patients with locally advanced (T3 or T4a) or high-grade muscle-invasive (T2) bladder cancer. Patients were randomly assigned to undergo either definitive treatment immediately or definitive treatment preceded by three cycles of neoadjuvant cisplatin, vinblastine, and methotrexate.[20,21] In this study, definitive treatment consisted of radical cystectomy (n = 428), radiation therapy (n = 403), or preoperative radiation therapy followed by radical cystectomy (n = 66).
A controlled trial of preoperative chemotherapy conducted by the Medical Research Council and the European Organisation for Research and Treatment of Cancer included 976 patients with locally advanced (T3 or T4a) or high-grade muscle-invasive (T2) bladder cancer. Patients were randomly assigned to undergo either definitive treatment immediately or definitive treatment preceded by three cycles of neoadjuvant cisplatin, vinblastine, and methotrexate.[20,21] In this study, definitive treatment consisted of radical cystectomy (n = 428), radiation therapy (n = 403), or preoperative radiation therapy followed by radical cystectomy (n = 66).
At a median follow-up of 8.0 years for patients still alive, OS was significantly greater in the arm randomly assigned to receive neoadjuvant chemotherapy (HR, 0.84; 95% CI, 0.72–0.99; P = .037). The survival benefit from neoadjuvant chemotherapy compared with definitive treatment alone conferred a 6% absolute increase in the likelihood of being alive at 3 years (56% vs. 50%), 5 years (49% vs. 43%), and 10 years (36% vs. 30%).[21][Level of evidence A1]
Sources: 21 · Level of evidence A1
A randomized study conducted by the Southwest Oncology Group compared three cycles of neoadjuvant cisplatin, methotrexate, vinblastine, and doxorubicin administered before cystectomy with cystectomy alone in 317 patients with stage T2 to stage T4a bladder cancer.[22]
Sources: 22
A randomized study conducted by the Southwest Oncology Group compared three cycles of neoadjuvant cisplatin, methotrexate, vinblastine, and doxorubicin administered before cystectomy with cystectomy alone in 317 patients with stage T2 to stage T4a bladder cancer.[22]
The study showed that the 5-year survival rate was 57% in the group that received neoadjuvant chemotherapy and 43% in the group treated with cystectomy alone. This difference was of borderline statistical significance (two-sided P value = .06 by stratified log-rank test).
No deaths were associated with neoadjuvant chemotherapy, and there was no difference in the rate or severity of postoperative complications in patients who received immediate surgery and in those who received preoperative chemotherapy. Cystectomy was performed as planned for 82% of patients assigned to preoperative chemotherapy and 81% of those assigned to cystectomy alone. This study provided evidence that preoperative chemotherapy does not prevent patients from undergoing cystectomy and does not increase the risk of perioperative complications.
Thirty-eight percent of patients who received neoadjuvant chemotherapy had a pathological complete response at the time of surgery, and 85% of those who achieved a pathological complete response were alive at 5 years.
A meta-analysis of ten randomized trials of neoadjuvant chemotherapy included updated data for 2,688 individual patients.[2]
Sources: 2
A meta-analysis of ten randomized trials of neoadjuvant chemotherapy included updated data for 2,688 individual patients.[2]
Cisplatin-based combination chemotherapy was associated with a significant 13% relative reduction in the risk of death and resulted in an improvement in 5-year survival rates from 45% to 50% (P = .016).
Neoadjuvant single-agent cisplatin was not associated with any survival benefit in the meta-analysis.
A subsequent meta-analysis evaluated a nearly identical body of data (11 randomized controlled trials enrolling a total of 2,605 patients) and reached similar conclusions. When the analysis was limited to the eight trials that used multiagent, cisplatin-based chemotherapy, neoadjuvant chemotherapy compared with cystectomy alone was associated with a 6.5% absolute benefit in the 5-year OS rate (56.5% vs. 50%; P = .006).[4]
Sources: 4
Most patients included in these studies received cisplatin, methotrexate, and vinblastine with or without doxorubicin. It is not known whether the doublet regimen of cisplatin plus gemcitabine offers any benefit when given in the preoperative setting, nor is there any evidence of benefit for carboplatin-based chemotherapy regimens.
Based on these findings, preoperative cisplatin-based combination chemotherapy followed by radical cystectomy represents a standard therapeutic option for patients with muscle-invasive bladder cancer who are fit for chemotherapy and for whom the priority is to maximize survival.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Numerous trials have investigated whether giving chemotherapy after radical cystectomy can improve progression-free survival (PFS) and OS. Although several trials showed a PFS benefit from postoperative cisplatin-based chemotherapy, the trials tended to be small and underpowered, and no trial demonstrated a persuasive benefit in OS.
Evidence (adjuvant chemotherapy):
A systematic review and meta-analysis evaluated nine randomized controlled trials that enrolled 945 patients. A variety of different cisplatin-based chemotherapy regimens were used.[23][Level of evidence A2]
Sources: 23 · Level of evidence A2
A systematic review and meta-analysis evaluated nine randomized controlled trials that enrolled 945 patients. A variety of different cisplatin-based chemotherapy regimens were used.[23][Level of evidence A2]
This analysis reported a significant OS benefit for patients who received adjuvant chemotherapy (HR, 0.77; 95% CI, 0.49–0.99).
The disease-free survival (DFS) benefit was similar (HR, 0.66; 95% CI, 0.45–0.91).
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Evidence (adjuvant immunotherapy):
A randomized controlled trial (Checkmate 274 [NCT02632409]) compared nivolumab with placebo in 709 patients with pathological T3, T4, or node-positive muscle-invasive urothelial carcinoma who had undergone radical cystectomy. Of note, the patients in this trial had either received preoperative cisplatin-based chemotherapy, refused postoperative cisplatin-based chemotherapy, or been deemed unfit for cisplatin-based chemotherapy.[24][Level of evidence A1]
Sources: Checkmate 274 · 24 · Level of evidence A1
A randomized controlled trial (Checkmate 274 [NCT02632409]) compared nivolumab with placebo in 709 patients with pathological T3, T4, or node-positive muscle-invasive urothelial carcinoma who had undergone radical cystectomy. Of note, the patients in this trial had either received preoperative cisplatin-based chemotherapy, refused postoperative cisplatin-based chemotherapy, or been deemed unfit for cisplatin-based chemotherapy.[24][Level of evidence A1]
At a median follow-up of 36.1 months, the OS was 69.6 months (95% CI, 58.1–not estimable [NE]) in the nivolumab arm and 50.1 months (95% CI, 38.2–NE) in the placebo arm (HR, 0.76; 95% CI, 0.61–0.96). In patients with programmed death-ligand 1 (PD-L1) expression of 1% or higher (approximately 40% of all enrolled patients), the median OS was not reached in either arm (HR, 0.56; 95% CI, 0.36–0.86).
The median DFS was 22.0 months (95% CI, 18.8–36.9) in the nivolumab arm and 10.9 months (95% CI, 8.3–15.2) in the placebo arm (HR, 0.71; 95% CI, 0.58–0.86). In patients with PD-L1 expression of 1% or greater, the median DFS was 52.6 months (95% CI, 25.8–NE) in the nivolumab arm and 8.4 months (95% CI, 5.6–17.9) in the placebo arm (HR, 0.52; 95% CI, 0.37–0.72).
In patients with PD-L1 expression of less than 1% in the intent-to-treat population, the HR for median DFS for nivolumab compared to placebo was 0.84 (95% CI, 0.66–1.06). In patients with PD-L1 expression of less than 1% and muscle-invasive bladder cancer (79% of enrolled patients), the median DFS was 18.3 months (95% CI, 14.1–22.4) in the nivolumab arm and 9.7 months (95% CI, 7.4–16.6) in the placebo arm (HR, 0.74; 95% CI, 0.56–0.97). OS data were not included in the supplement for patients with PD-L1 expression of less than 1%.
Grade 3 or higher adverse events were seen in 42.7% of patients in the nivolumab arm and 36.8% of patients in the placebo arm. High-grade treatment-related adverse events were seen in 18.2% of patients in the nivolumab arm and 7.2% of patients in the placebo arm. The most common adverse events were pruritus, fatigue, and diarrhea, while the most common grade 3 or higher adverse events were elevated lipase or amylase, diarrhea, colitis, and pneumonitis. Two patients in the nivolumab arm died of pneumonitis, and one patient died of a bowel perforation.
A randomized controlled trial (AMBASSADOR [NCT03244384]) compared adjuvant pembrolizumab with observation in 702 patients. Patients had undergone radical cystectomy and had positive margins, node-positive disease, and either pathological T2 or higher stage disease (if neoadjuvant cisplatin-based chemotherapy was received) or T3 or higher disease (if no neoadjuvant chemotherapy had been received).[25][Level of evidence B1]
Sources: AMBASSADOR · 25 · Level of evidence B1
A randomized controlled trial (AMBASSADOR [NCT03244384]) compared adjuvant pembrolizumab with observation in 702 patients. Patients had undergone radical cystectomy and had positive margins, node-positive disease, and either pathological T2 or higher stage disease (if neoadjuvant cisplatin-based chemotherapy was received) or T3 or higher disease (if no neoadjuvant chemotherapy had been received).[25][Level of evidence B1]
At a median follow-up of 44.8 months, the DFS was 26.9 months (95% CI, 20.0–40.7) in the pembrolizumab arm and 14.2 months (95% CI, 11.0–20.2) in the observation arm (HR, 0.73; 95% CI, 0.59–0.90).
In patients with a PD-L1 combined positive score (CPS) of at least 10 (57.5% of all enrolled patients), the median DFS was 36.9 months (95% CI, 27.2–NE) in the pembrolizumab arm and 21.0 months (95% CI, 13.6–53.3) in the observation arm (HR, 0.81; 95% CI, 0.61–1.08). In patients with a PD–L1 CPS less than 10 (42.5% of all enrolled patients), the median DFS was 17.3 months (95% CI, 13.2–32.0) in the pembrolizumab arm and 9.0 months (95% CI, 6.9–15.3) in the observation arm (HR, 0.71; 95% CI, 0.53–0.95).
The 3-year OS rate was not significantly different, at 60.5% for patients in the pembrolizumab arm and 61.9% for patients in the observation arm (HR, 0.98; 95% CI, 0.76–1.26).
Grade 3 or higher adverse events occurred in 50.6% of patients in the pembrolizumab arm and 31.6% of patients in the observation arm.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Definitive radiation therapy is a standard option that yields 5-year survival rates of approximately 30% to 40%.[26] When radiation therapy and chemotherapy are administered concomitantly, the results are better. However, while the addition of chemotherapy to radiation therapy has been shown to reduce local relapse rates, it has not been shown to result in increased survival, decreased mortality, or improved quality of life.
Sources: 26
Most protocols for bladder preservation that use combined chemotherapy and radiation therapy have followed a relatively complex algorithm. After the initial stage TUR of the bladder tumor, patients undergo a repeat TUR to maximally resect the tumor. The patient is then treated with synchronous chemoradiation therapy to a dose of roughly 40 Gy followed by a repeat cystoscopy with biopsies to assess for residual cancer. If residual cancer is detected histopathologically, then the chemoradiation therapy is judged to have failed and the patient is advised to undergo a radical cystectomy. If the biopsies at 40 Gy are benign, then chemoradiation therapy is completed to a dose of about 65 Gy.
With definitive radiation therapy, best results are seen in patients with solitary lesions and without carcinoma in situ or hydronephrosis.
After radiation therapy, approximately 50% of patients have dysuria and urinary frequency during treatment, which resolves several weeks after treatment, and 15% report acute toxic effects of the bowel.
Randomized trials that directly compare the bladder-preserving chemoradiation therapy approach with radical cystectomy have not been performed. The relative effectiveness of these two treatments is thus unknown.
Evidence (EBRT with or without concomitant chemotherapy):
TUR followed by chemoradiation therapy
A multicenter phase III trial randomly assigned 360 patients with muscle-invasive bladder cancer to radiation therapy with or without synchronous chemotherapy using fluorouracil and mitomycin.[26]
Sources: 26
A multicenter phase III trial randomly assigned 360 patients with muscle-invasive bladder cancer to radiation therapy with or without synchronous chemotherapy using fluorouracil and mitomycin.[26]
The 2-year locoregional DFS rate was higher in the chemoradiation therapy group (67% vs. 54%; HR, 0.68; 95% CI, 0.48–0.96; P = .03). The 5-year OS rate was 48% in the chemoradiation therapy group and 35% in the radiation therapy group, but the difference was not statistically significant (P = .16).
Similarly, synchronous chemoradiation therapy using other chemotherapy regimens, such as cisplatin alone or combined with fluorouracil, have reported 5-year OS rates of 50% to 60% and survival with an intact bladder in 40% to 45% of patients. These figures are higher than what has generally been reported in studies of radiation therapy alone.[27]
Sources: 27
TUR followed by chemoradiation therapy
In some nonrandomized studies, 50% or more of the patients who underwent bladder-preserving therapy (i.e., initial TUR of as much tumor as possible followed by concurrent chemoradiation therapy) were alive at 5 years, and 75% of those survivors had an intact bladder.[28-30]
Radiation therapy and chemotherapy
A randomized controlled trial randomly assigned 99 patients with T2 to T4b urothelial carcinoma of the bladder to radiation therapy with or without three 14-day cycles of cisplatin (100 mg/m2 on day 1). Patients and their physicians chose whether the radiation therapy was definitive or given as precystectomy treatment.[31]
Sources: 31
A randomized controlled trial randomly assigned 99 patients with T2 to T4b urothelial carcinoma of the bladder to radiation therapy with or without three 14-day cycles of cisplatin (100 mg/m2 on day 1). Patients and their physicians chose whether the radiation therapy was definitive or given as precystectomy treatment.[31]
The pelvic relapse rate was reduced (multivariable regression model HR, 0.50; 90% CI, 0.29–0.86; P = .036) using concurrent cisplatin, but there was no difference in the occurrence of distant metastases or OS.
The reduction in pelvic relapse was similar in patients who received definitive radiation therapy and precystectomy radiation therapy.
Neoadjuvant chemotherapy followed by chemoradiation therapy
In a phase III study (RTOG-8903), the Radiation Therapy Oncology Group evaluated the potential benefit of adding two cycles of neoadjuvant methotrexate, cisplatin, and vinblastine before concurrent cisplatin and radiation therapy.[32]
Sources: 32
In a phase III study (RTOG-8903), the Radiation Therapy Oncology Group evaluated the potential benefit of adding two cycles of neoadjuvant methotrexate, cisplatin, and vinblastine before concurrent cisplatin and radiation therapy.[32]
Neoadjuvant chemotherapy was associated with increased hematologic toxic effects and yielded no improvement in response rate, freedom from distant metastases, or OS compared with chemoradiation therapy alone.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Segmental cystectomy is appropriate only in very selected patients.[1] There are no randomized controlled trials comparing segmental cystectomy with radical cystectomy. Only patients with adenocarcinomas of the urachus are routinely treated with segmental cystectomy. These tumors typically are mucinous adenocarcinomas occurring at the dome of the bladder and are treated with an en bloc resection of the bladder dome and urachal remnant, including the umbilicus.[33-36]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
TUR may control stage II bladder cancer in some patients. However, more aggressive forms of treatment are often dictated by recurrent tumor or by the large size, multiple foci, or undifferentiated grade of the neoplasm.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Few patients with stage IV bladder cancer can be cured, and for many patients, the emphasis is on palliation of symptoms. The potential for cure is restricted to patients with stage IV disease with involvement of pelvic organs by direct extension or metastases to regional lymph nodes.[1]
Sources: stage IV bladder cancer · 1
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Treatment options for patients with T4b, N0, M0 disease include:
Enfortumab vedotin plus pembrolizumab.
Chemotherapy plus immunotherapy.
Sources: Chemotherapy plus immunotherapy
Chemotherapy alone.
Sources: Chemotherapy alone
Systemic therapy followed by radical cystectomy.
External-beam radiation therapy (EBRT) with or without concomitant chemotherapy.
Sources: External-beam radiation therapy
Urinary diversion or cystectomy for palliation.
Sources: Urinary diversion or cystectomy
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Enfortumab vedotin is an antibody-drug conjugate, combining an antibody that binds to nectin-4 with a microtubule inhibitor. The U.S. Food and Drug Administration (FDA) approved enfortumab vedotin as monotherapy for patients with previously treated metastatic urothelial carcinoma. Pembrolizumab is an anti−programmed death-1 (PD-1) antibody that the FDA has approved as monotherapy for patients with metastatic bladder cancer. The combination of the two agents showed a promising response rate and duration of response, leading to a single-arm phase II trial and then a comparison with chemotherapy in a randomized, controlled, phase III trial.[2-4] While results cannot be extrapolated across trials, enfortumab vedotin plus pembrolizumab is a first-line therapy option for patients without a contraindication.
Evidence (enfortumab vedotin plus pembrolizumab):
In a phase III trial (EV-302 [NCT04223856]), 886 patients were randomly assigned to receive either enfortumab vedotin plus pembrolizumab (n = 442) or gemcitabine plus either cisplatin or carboplatin (n = 444). The median follow-up was 17.2 months.[4][Level of evidence A1]
Sources: EV-302 · 4 · Level of evidence A1
In a phase III trial (EV-302 [NCT04223856]), 886 patients were randomly assigned to receive either enfortumab vedotin plus pembrolizumab (n = 442) or gemcitabine plus either cisplatin or carboplatin (n = 444). The median follow-up was 17.2 months.[4][Level of evidence A1]
Overall survival (OS) and progression-free survival (PFS) were longer for patients in the enfortumab vedotin-plus-pembrolizumab arm than in the chemotherapy arm.
The median OS was 31.5 months for patients who received enfortumab vedotin plus pembrolizumab and 16.1 months for patients who received chemotherapy (hazard ratio [HR], 0.47; 95% confidence interval [CI], 0.38–0.58; P < .001).
PFS was 12.5 months for patients who received enfortumab vedotin plus pembrolizumab and 6.3 months for patients who received chemotherapy (HR, 0.45; 95% CI, 0.38–0.54; P < .001).
Grade 3 or higher adverse events occurred in 55.9% of patients who received enfortumab vedotin plus pembrolizumab and 69.5% of patients who received chemotherapy.
In the experimental arm, the most common high-grade adverse events were skin reactions, peripheral neuropathy, hyperglycemia, and neutropenia.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
For many years, cisplatin-based chemotherapy was the standard-of-care first-line systemic treatment for patients with stage IV urothelial carcinoma who were eligible to receive cisplatin. A randomized, controlled, phase III trial reported longer OS when cisplatin-based chemotherapy was given with nivolumab, compared with chemotherapy alone.[5]
Sources: 5
Evidence (chemotherapy plus immunotherapy):
A phase III, randomized controlled trial (CheckMate901 [NCT03036098]) included 608 patients (304 to each arm). Patients were randomly assigned to receive either nivolumab plus gemcitabine and cisplatin or gemcitabine and cisplatin alone. Patients received up to six cycles of chemotherapy and up to 2 years of nivolumab. The median follow-up was 33.6 months.[5]
Sources: CheckMate901 · 5
A phase III, randomized controlled trial (CheckMate901 [NCT03036098]) included 608 patients (304 to each arm). Patients were randomly assigned to receive either nivolumab plus gemcitabine and cisplatin or gemcitabine and cisplatin alone. Patients received up to six cycles of chemotherapy and up to 2 years of nivolumab. The median follow-up was 33.6 months.[5]
The median OS was 21.7 months for patients who received nivolumab and 18.9 months for patients who received chemotherapy alone (HRdeath, 0.78; 95% CI, 0.63–0.96; P = .02).[5][Level of evidence A1]
Sources: 5 · Level of evidence A1
The median PFS was 7.9 months for patients who received nivolumab and 7.6 months for patients who received chemotherapy alone (HRprogression or death, 0.72; 95% CI, 0.59–0.88; P = .001).
At 1 year, the PFS rate was 34.2% in the nivolumab arm and 21.8% in the chemotherapy-alone arm.
The overall response rate was 57.6% in the nivolumab arm and 21.7% in the chemotherapy-alone arm. The complete response rate was 21.7% in the nivolumab arm and 11.8% in the chemotherapy-alone arm.
The duration of complete response was 37.1 months in the nivolumab arm and 13.2 months in the chemotherapy-alone arm.
Grade 3 or higher adverse events occurred in 61.8% of patients in the nivolumab arm and 51.7% of patients in the chemotherapy-alone arm.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Cisplatin-based combination chemotherapy regimens are a standard-of-care option for patients with stage IV bladder cancer.[6-10] The only chemotherapy regimens that have been shown to result in longer survival in randomized controlled trials are methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC); high-dose MVAC; and cisplatin, methotrexate, and vinblastine (CMV). Gemcitabine plus cisplatin (GC) was compared with MVAC in a randomized controlled trial that reported no difference in response rate or survival. Of note, patients with good performance status and lymph node–only disease have a low but significant rate of achieving a durable complete remission with MVAC or GC. For example, in a large, randomized controlled trial that compared MVAC with GC, the 5-year OS rate was 20.9% in patients with lymph node–only disease.[11]
Single-agent cisplatin and multiagent regimens that do not include cisplatin have never resulted in improved survival in a randomized controlled trial. For patients who are not candidates for cisplatin-based multiagent chemotherapy regimens, there is no regimen that has been shown to prolong survival. However, many regimens have demonstrated radiologically measurable responses.
These regimens include carboplatin plus paclitaxel,[12] carboplatin plus gemcitabine,[13-15] paclitaxel plus gemcitabine,[16-18] single-agent gemcitabine,[19,20] and single-agent paclitaxel.[21-23] Regimens of carboplatin, methotrexate, and vinblastine; carboplatin, epirubicin, methotrexate, and vinblastine; and paclitaxel, gemcitabine, and carboplatin have been studied but are not widely used.[24-27]
Sources: 12 · 13 · 15 · 16 · 18 · 19 · 20 · 21 · 23 · 24 · 27
Evidence (chemotherapy alone):
Results from a randomized controlled trial that compared MVAC with docetaxel plus cisplatin in 220 patients reported that MVAC was associated with longer OS (median survival, 14.2 months vs. 9.3 months; P = .026).[28]
Sources: 28
A randomized trial that compared MVAC with cisplatin, cyclophosphamide, and doxorubicin demonstrated improved response and median survival rates (48 weeks vs. 36 weeks; P = .003) with the MVAC regimen.[29]
Sources: 29
Results from a randomized trial that compared MVAC with single-agent cisplatin in advanced bladder cancer also showed a significant advantage with MVAC in both response rate and median survival (12.5 months vs. 8.2 months; P = .002).[30]
Sources: 30
A multicenter randomized controlled trial compared CMV with methotrexate plus vinblastine without cisplatin in 214 patients. The relative risk of dying was 0.68 (95% CI, 0.51–0.90; P = .0065) in favor of CMV. The median survival was 7 months with CMV and 4.5 months with methotrexate plus vinblastine.[31]
Sources: 31
The European Organisation for Research and Treatment of Cancer (EORTC) conducted a randomized trial that included 263 patients with advanced bladder cancer. The study evaluated the efficacy of a high-dose intensity MVAC regimen given every 2 weeks with granulocyte colony-stimulating factor (G-CSF) versus a classic MVAC regimen given every 4 weeks.[32]
Sources: 32
The European Organisation for Research and Treatment of Cancer (EORTC) conducted a randomized trial that included 263 patients with advanced bladder cancer. The study evaluated the efficacy of a high-dose intensity MVAC regimen given every 2 weeks with granulocyte colony-stimulating factor (G-CSF) versus a classic MVAC regimen given every 4 weeks.[32]
There was no significant difference in OS at a median follow-up of 3.2 years (HR, 0.80; 95% CI, 0.60–1.06; P = .122). However, at a median follow-up of 7.3 years, the high-dose intensity MVAC regimen was associated with improved OS (HR, 0.76; 95% CI, 0.58–0.99; P = .042), with a 5-year survival rate of 22% compared with 14% in patients treated with the classic MVAC regimen.
The high-dose intensity MVAC regimen was also associated with higher response rates (72% vs. 58%; P = .016), improved median PFS (9.5 months vs. 8.1 months; P = .017), and decreased neutropenic fever (10% vs. 26%; P < .001), although only 19% of patients treated with a classic MVAC regimen ever received G-CSF.[32][Level of evidence A1] An imbalance in baseline prognostic factors (i.e., visceral metastases were found in 37 patients randomly assigned to the high-dose MVAC regimen and 47 patients assigned to the classic MVAC regimen) may account, in part, for these results.
Sources: 32 · Level of evidence A1
A multicenter, randomized, phase III trial compared GC with MVAC in 405 patients with advanced or metastatic bladder cancer.
A multicenter, randomized, phase III trial compared GC with MVAC in 405 patients with advanced or metastatic bladder cancer.
GC yielded response rates, time-to-progression, and OS (HR, 1.04; 95% CI, 0.82–1.32; P = .75) similar to MVAC, but GC had a better safety profile and was better tolerated than MVAC.[33][Level of evidence A1]
Sources: 33 · Level of evidence A1
Although this study was not designed to show the equivalence of the two regimens, the similar efficacy and reduced toxic effects of GC make it a reasonable alternative in patients who may not tolerate the MVAC regimen.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Definitive radiation therapy with or without concurrent chemotherapy, evaluated mainly in patients with locally advanced (T2–T4) disease, appears to have minimal curative potential in patients with regional lymph node metastases.[34,35] Patients with evidence of lymph node metastases have generally been excluded from phase III trials of radiation therapy.[36,37]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Urinary diversion may be indicated, not only for palliation of urinary symptoms but also for preservation of renal function in patients who are candidates for chemotherapy.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Treatment options for patients with any T, any N, M1 disease include:
Enfortumab vedotin plus pembrolizumab.
Chemotherapy plus immunotherapy.
Sources: Chemotherapy plus immunotherapy
Chemotherapy alone or as an adjunct to local treatment.
Sources: Chemotherapy alone or as an adjunct to local treatment
Immunotherapy.
Sources: Immunotherapy
EBRT for palliation.
Sources: EBRT
Urinary diversion or cystectomy for palliation.
Sources: Urinary diversion or cystectomy
Other chemotherapy agents with activity in metastatic bladder cancer, such as paclitaxel, docetaxel, and ifosfamide (under clinical evaluation).[38,39][Level of evidence C3]
Sources: 38 · 39 · Level of evidence C3
Clinical trials.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Enfortumab vedotin is an antibody-drug conjugate, combining an antibody that binds to nectin-4 with a microtubule inhibitor. The FDA approved enfortumab vedotin as monotherapy for patients with previously treated metastatic urothelial carcinoma. Pembrolizumab is an anti–PD-1 antibody that has been approved as monotherapy for patients with metastatic bladder cancer. The combination of the two agents showed a promising response rate and duration of response, leading to a single-arm phase II trial and then a comparison with chemotherapy in a phase III, randomized controlled trial.[2-4] While results cannot be extrapolated across trials, enfortumab vedotin plus pembrolizumab is a first-line therapy option for patients without a contraindication.
Evidence (enfortumab vedotin plus pembrolizumab):
In a phase III trial (EV-302 [NCT04223856]), 886 patients were randomly assigned to receive either enfortumab vedotin plus pembrolizumab (n = 442) or gemcitabine plus either cisplatin or carboplatin (n = 444). The median follow-up was 17.2 months.[4][Level of evidence A1]
Sources: EV-302 · 4 · Level of evidence A1
In a phase III trial (EV-302 [NCT04223856]), 886 patients were randomly assigned to receive either enfortumab vedotin plus pembrolizumab (n = 442) or gemcitabine plus either cisplatin or carboplatin (n = 444). The median follow-up was 17.2 months.[4][Level of evidence A1]
OS and PFS were longer for patients in the enfortumab vedotin-plus-pembrolizumab arm than in the chemotherapy arm.
The median OS was 31.5 months for patients who received enfortumab vedotin plus pembrolizumab and 16.1 months for patients who received chemotherapy (HR, 0.47; 95% CI, 0.38–0.58; P < .001).
PFS was 12.5 months for patients who received enfortumab vedotin plus pembrolizumab and 6.3 months for patients who received chemotherapy (HR, 0.45; 95% CI, 0.38–0.54; P < .001).
Grade 3 or higher adverse events occurred in 55.9% of patients who received enfortumab vedotin plus pembrolizumab and 69.5% of patients who received chemotherapy.
In the experimental arm, the most common high-grade adverse events were skin reactions, peripheral neuropathy, hyperglycemia, and neutropenia.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
For many years, cisplatin-based chemotherapy was the standard-of-care first-line systemic treatment for patients with stage IV urothelial carcinoma who were eligible to receive cisplatin. A randomized, controlled, phase III trial reported longer OS when cisplatin-based chemotherapy was given with nivolumab, compared with chemotherapy alone.[5]
Sources: 5
Evidence (chemotherapy plus immunotherapy):
A phase III, randomized controlled trial (CheckMate901 [NCT03036098]) included 608 patients (304 to each arm). Patients were randomly assigned to receive either nivolumab plus gemcitabine and cisplatin or gemcitabine and cisplatin alone. Patients received up to six cycles of chemotherapy and up to 2 years of nivolumab. The median follow-up was 33.6 months.[5]
Sources: CheckMate901 · 5
A phase III, randomized controlled trial (CheckMate901 [NCT03036098]) included 608 patients (304 to each arm). Patients were randomly assigned to receive either nivolumab plus gemcitabine and cisplatin or gemcitabine and cisplatin alone. Patients received up to six cycles of chemotherapy and up to 2 years of nivolumab. The median follow-up was 33.6 months.[5]
The median OS was 21.7 months for patients who received nivolumab and 18.9 months for patients who received chemotherapy alone (HRdeath, 0.78; 95% CI, 0.63–0.96; P = .02).[5][Level of evidence A1]
Sources: 5 · Level of evidence A1
The median PFS was 7.9 months for patients who received nivolumab and 7.6 months for patients who received chemotherapy alone (HRprogression or death, 0.72; 95% CI, 0.59–0.88; P = .001).
At 1 year, the PFS rate was 34.2% in the nivolumab arm and 21.8% in the chemotherapy-alone arm.
The overall response rate was 57.6% in the nivolumab arm and 21.7% in the chemotherapy-alone arm. The complete response rate was 21.7% in the nivolumab arm and 11.8% in the chemotherapy-alone arm.
The duration of complete response was 37.1 months in the nivolumab arm and 13.2 months in the chemotherapy-alone arm.
Grade 3 or higher adverse events occurred in 61.8% of patients in the nivolumab arm and 51.7% of patients in the chemotherapy-alone arm.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Cisplatin-based combination chemotherapy regimens are the standard of care for first-line therapy for stage IV bladder cancer in patients who can tolerate it.[6-10] The only chemotherapy regimens that have been shown to result in longer survival in randomized controlled trials are MVAC, dose-dense MVAC, and CMV. GC was compared with MVAC in a randomized controlled trial and neither regimen was associated with a statistically significant difference in response rate or survival. The two regimens are generally considered equivalent, but they have never been compared in a noninferiority trial. Of note, patients with good performance status and lymph node–only disease have a low but significant rate of achieving a durable complete remission with MVAC or GC. For example, in a large, randomized controlled trial that compared MVAC with GC, the 5-year OS rate was 20.9% in patients with lymph node–only disease.[11] Dose-dense MVAC and standard-dose MVAC were compared in a randomized controlled trial, and dose-dense MVAC was associated with longer survival.
Single-agent cisplatin and multiagent regimens that do not include cisplatin have never resulted in improved survival in a randomized controlled trial. For patients who are not candidates for cisplatin-based multiagent chemotherapy regimens, there is no regimen that has been shown to prolong survival. However, many regimens have demonstrated radiologically measurable responses.
These regimens include carboplatin plus paclitaxel,[12] carboplatin plus gemcitabine,[13-15] paclitaxel plus gemcitabine,[16-18] single-agent gemcitabine,[19,20] and single-agent paclitaxel.[21-23] The regimens of carboplatin, methotrexate, and vinblastine; carboplatin, epirubicin, methotrexate, and vinblastine; and paclitaxel, gemcitabine, and carboplatin have been studied but are not widely used.[24-27]
Sources: 12 · 13 · 15 · 16 · 18 · 19 · 20 · 21 · 23 · 24 · 27
Ongoing studies are evaluating new chemotherapy combinations.
Evidence (chemotherapy):
A prospective randomized trial that compared MVAC with cisplatin, cyclophosphamide, and doxorubicin demonstrated improved response rate and longer median survival (48 weeks vs. 36 weeks; P = .003) with the MVAC regimen.[29]
Sources: 29
Results from a randomized trial that compared MVAC with single-agent cisplatin in advanced bladder cancer also showed a significant advantage with MVAC in both response rate and median survival (12.5 months vs. 8.2 months; P = .002).[30]
Sources: 30
A multicenter randomized controlled trial compared CMV with methotrexate plus vinblastine without cisplatin in 214 patients. The relative risk of dying was 0.68 (95% CI, 0.51–0.90; P = .0065) in favor of CMV. The median survival was 7 months with CMV compared with 4.5 months for methotrexate plus vinblastine.[31]
Sources: 31
The EORTC conducted a randomized trial that included 263 patients with advanced bladder cancer. The study evaluated the efficacy of a high-dose intensity MVAC regimen given every 2 weeks with G-CSF compared with a classic MVAC regimen given every 4 weeks.[32]
Sources: 32
The EORTC conducted a randomized trial that included 263 patients with advanced bladder cancer. The study evaluated the efficacy of a high-dose intensity MVAC regimen given every 2 weeks with G-CSF compared with a classic MVAC regimen given every 4 weeks.[32]
There was no significant difference in OS at a median follow-up of 3.2 years (HR, 0.80; 95% CI, 0.60–1.06; P = .122). However, at a median follow-up of 7.3 years, the high-dose intensity MVAC regimen was associated with improved OS (HR, 0.76; 95% CI, 0.58–0.99; P = .042), with a 5-year survival rate of 22%, compared with 14% in patients treated with the classic MVAC regimen.
The high-dose intensity MVAC regimen was also associated with higher response rates (72% vs. 58%; P = .016), improved median PFS (9.5 months vs. 8.1 months; P = .017), and decreased neutropenic fever (10% vs. 26%, P < .001), although only 19% of patients treated with a classic MVAC regimen ever received G-CSF.[32][Level of evidence A1] An imbalance in baseline prognostic factors (i.e., visceral metastases were found in 37 patients randomly assigned to the high-dose MVAC regimen and 47 patients assigned to the classic MVAC regimen) may account, in part, for these results.
Sources: 32 · Level of evidence A1
A multicenter, randomized, phase III trial compared GC with MVAC in 405 patients with advanced or metastatic bladder cancer.
A multicenter, randomized, phase III trial compared GC with MVAC in 405 patients with advanced or metastatic bladder cancer.
GC yielded response rates, time-to-progression, and OS (HR, 1.04; 95% CI, 0.82–1.32; P = .75) similar to MVAC, but GC had a better safety profile and was better tolerated than MVAC.[33][Level of evidence A1]
Sources: 33 · Level of evidence A1
Although this study was not designed to show the equivalence of the two regimens, the similar efficacy and reduced toxic effects of GC make it a reasonable alternative in patients who may not tolerate the MVAC regimen.
Other chemotherapy regimens that have shown activity in metastatic bladder cancer include single-agent paclitaxel, single-agent gemcitabine, single-agent pemetrexed, carboplatin combined with either gemcitabine or paclitaxel, and gemcitabine combined with paclitaxel. There are no phase III trials demonstrating a survival or quality-of-life benefit from second-line chemotherapy.[13,16,18,19,27,40-52]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Immunotherapy has emerged as a treatment alternative for patients with stage IV bladder cancer. Anti−PD-1 or anti−programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors have activity against urothelial carcinoma in patients who have previously been treated with, or who are ineligible for, platinum-based chemotherapy.[53-57] There are several approved agents. However, pembrolizumab has the most robust data in terms of level of evidence and survival rates.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Pembrolizumab is a humanized monoclonal antibody that binds to PD-1. In patients previously treated with platinum-based chemotherapy, pembrolizumab has prolonged OS compared with second-line chemotherapy. As a result, the FDA approved pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma who fall into one of the following three categories:
Cisplatin-ineligible and have tumors that express PD-L1 (combined positive score [CPS] of at least 10).
Cisplatin- and carboplatin-ineligible.
Progression of disease after treatment with platinum-based chemotherapy.
Evidence (pembrolizumab):
An open-label, international, randomized controlled, phase III trial (NCT02256436) included patients whose disease had progressed after treatment with platinum-based chemotherapy. Patients received pembrolizumab (200 mg intravenously [IV] every 21 days) or second-line chemotherapy (investigator’s choice of paclitaxel, docetaxel, or vinflunine).[58]
Sources: NCT02256436 · 58
An open-label, international, randomized controlled, phase III trial (NCT02256436) included patients whose disease had progressed after treatment with platinum-based chemotherapy. Patients received pembrolizumab (200 mg intravenously [IV] every 21 days) or second-line chemotherapy (investigator’s choice of paclitaxel, docetaxel, or vinflunine).[58]
The median OS was longer with pembrolizumab (10.3 months vs. 7.4 months; HR, 0.73; 95% CI, 0.59–0.91).
In patients with a PD-L1 CPS of at least 10, the median OS was 8.0 months with pembrolizumab compared with 5.2 months of chemotherapy (HR, 0.57; 95% CI, 0.37–0.88).
The PFS rate at 12 months was 16.8% (95% CI, 12.3%–22.0%) in the pembrolizumab arm and 6.2% (95% CI, 3.3%–10.2%) in the chemotherapy arm.
The objective response rate was 21.1% in the pembrolizumab arm and 11.4% in the chemotherapy arm. Among those who responded, the median duration of response was longer than 18 months with pembrolizumab compared with a response of 4.3 months with chemotherapy.
Pembrolizumab was associated with a lower rate of treatment-related adverse events than chemotherapy (60.9% vs. 90.2%) and a lower rate of high-grade adverse events (15.0% vs. 49.4%). The most common adverse events with pembrolizumab were pruritus, fatigue, nausea, diarrhea, and decreased appetite.[58][Level of evidence A1]
Sources: 58 · Level of evidence A1
A single-arm, phase II trial (NCT02335424) of pembrolizumab included 370 treatment-naïve, cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.[59]
Sources: NCT02335424 · 59
A single-arm, phase II trial (NCT02335424) of pembrolizumab included 370 treatment-naïve, cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.[59]
The overall response rate was 29%. In patients with a PD-L1 CPS of at least 10, the overall response rate was 51%.[59][Level of evidence C3]
Sources: 59 · Level of evidence C3
The median duration of response had not been reached. Eighty-two percent of responses lasted at least 6 months.
Ten percent of patients had a serious treatment-related adverse event, and one patient died of treatment-related adverse events. The most common high-grade adverse events were fatigue (2%), elevated alkaline phosphatase (1%), colitis (1%), and muscle weakness (1%).
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Atezolizumab is a humanized monoclonal antibody that binds to PD-L1 and prevents it from binding to its receptors, PD-1 or B7-1. Atezolizumab was voluntarily withdrawn in 2022 as a first-line treatment option for locally advanced or metastatic urothelial cancer. The withdrawal was based on the results of the randomized IMvigor130 trial (NCT02807636) which showed no significant difference in OS. No survival improvement was seen in two analyses: atezolizumab plus platinum-based chemotherapy (group A) versus placebo plus platinum-based chemotherapy (group C),[60][Level of evidence A1] and atezolizumab monotherapy (group B) versus group C.[61][Level of evidence A1]
Sources: IMvigor130 · 60 · Level of evidence A1 · 61 · Level of evidence A1
The trials below examined the use of atezolizumab as a first-line therapy in cisplatin-eligible patients.
Evidence (atezolizumab):
A multicenter single-arm trial (NCT0108652) included 315 cisplatin-ineligible patients or patients who were previously treated with platinum-based chemotherapy and who had inoperable locally advanced or metastatic urothelial carcinoma. Patients received atezolizumab (1,200 mg IV every 21 days).[56][Level of evidence C2]
Sources: NCT0108652 · 56 · Level of evidence C2
A multicenter single-arm trial (NCT0108652) included 315 cisplatin-ineligible patients or patients who were previously treated with platinum-based chemotherapy and who had inoperable locally advanced or metastatic urothelial carcinoma. Patients received atezolizumab (1,200 mg IV every 21 days).[56][Level of evidence C2]
The overall response rate was 15%.
With a median follow-up of 11.7 months, 38 of 45 responders (84%) had an ongoing response.
The response rate was 27% in patients with PD-L1 expression of at least 5%, 10% in those with PD-L1 expression of 1% to 5%, and 8% in those with PD-L1 expression of less than 1%.
Grade 3 to 4 adverse events were reported in 16% of patients, and high-grade, immune-related adverse events were reported in 5% of patients.
Similarly, a study (NCT02108652) of 123 previously untreated patients with cisplatin-ineligible, locally advanced metastatic urothelial carcinoma who were treated with atezolizumab reported that at a median follow-up of 17.2 months, the objective response rate was 23%, and 9% had complete responses.[57][Level of evidence C2]
Sources: NCT02108652 · 57 · Level of evidence C2
Similarly, a study (NCT02108652) of 123 previously untreated patients with cisplatin-ineligible, locally advanced metastatic urothelial carcinoma who were treated with atezolizumab reported that at a median follow-up of 17.2 months, the objective response rate was 23%, and 9% had complete responses.[57][Level of evidence C2]
Of the 27 responses, 19 were ongoing at the time of data analysis. Median OS was 15.9 months.
High-grade adverse events were reported in 16% of patients, 8% of patients discontinued treatment because of the adverse events, and there was one treatment-related death.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Nivolumab is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody that blocks interaction between PD-L1 and PD-L2 with PD-1. There are no published controlled trials and thus no data regarding whether nivolumab results in longer survival or improved quality of life.
Evidence (nivolumab):
A multicenter trial (NCT01928394) included 86 patients with metastatic urothelial carcinoma whose disease progressed after platinum-based chemotherapy. Patients received nivolumab (3 mg/kg IV every 2 weeks).[55][Level of evidence B4]
Sources: NCT01928394 · 55 · Level of evidence B4
A multicenter trial (NCT01928394) included 86 patients with metastatic urothelial carcinoma whose disease progressed after platinum-based chemotherapy. Patients received nivolumab (3 mg/kg IV every 2 weeks).[55][Level of evidence B4]
With a minimum follow-up of 9 months and a median follow-up of 15 months, 24% of patients had an objective response, and 22% had grade 3 or 4 adverse events.
The most common adverse events were elevated lipase or amylase, fatigue, rash, dyspnea, lymphopenia, and neutropenia.
Another multicenter study (NCT02387996) of 270 patients with locally advanced or metastatic urothelial carcinoma that had progressed after treatment with platinum-based chemotherapy reported an objective response rate of 20%.[54][Level of evidence B4]
Sources: NCT02387996 · 54 · Level of evidence B4
Another multicenter study (NCT02387996) of 270 patients with locally advanced or metastatic urothelial carcinoma that had progressed after treatment with platinum-based chemotherapy reported an objective response rate of 20%.[54][Level of evidence B4]
When evaluated by PD-L1 expression, the objective response rate was 28% in those with PD-L1 expression of 5% or greater; 24% in those with PD-L1 expression of 1% or greater; and 16% in those with PD-L1 expression of less than 1%.
Grade 3 to 4 adverse events were reported in 18% of patients.
There were three treatment-related deaths.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Avelumab is a monoclonal anti–PD-L1 antibody that has shown activity against urothelial carcinoma. A randomized controlled trial reported an OS benefit from maintenance avelumab when given after platinum-based chemotherapy in patients whose cancer did not progress during chemotherapy.
Evidence (avelumab):
A phase III study (NCT02603432) evaluated maintenance avelumab (10 mg/kg IV every 14 days) in patients with metastatic urothelial carcinoma who had not progressed during treatment with first-line chemotherapy with gemcitabine combined with either cisplatin or carboplatin. After four to six cycles of chemotherapy, 700 patients were randomly assigned to receive either best supportive care (control arm) or best supportive care plus maintenance avelumab (avelumab arm).[62][Level of evidence A1]
Sources: NCT02603432 · 62 · Level of evidence A1
A phase III study (NCT02603432) evaluated maintenance avelumab (10 mg/kg IV every 14 days) in patients with metastatic urothelial carcinoma who had not progressed during treatment with first-line chemotherapy with gemcitabine combined with either cisplatin or carboplatin. After four to six cycles of chemotherapy, 700 patients were randomly assigned to receive either best supportive care (control arm) or best supportive care plus maintenance avelumab (avelumab arm).[62][Level of evidence A1]
The 1-year OS rate was 71.3% in the avelumab arm compared with 58.4% in the control arm (HR, 0.69; 95% CI, 0.56–0.86).
The OS benefit was limited to patients whose tumors were PD-L1 positive. The OS in patients with PD-L1–negative tumors was not significantly different between the two arms.
Patients with PD-L1–positive tumors had a 1-year OS rate of 79.1% in the avelumab arm and 60.4% in the control arm (HR, 0.56; 95% CI, 0.40–0.79).
In the overall study population, the median PFS was 3.7 months for patients in the avelumab arm and 2.0 months for patients in the control arm (HR, 0.62; 95% CI, 0.52–0.75). In patients with PD-L1–positive tumors, the median PFS was 5.7 months with avelumab and 2.1 months with best supportive care alone (HR, 0.56; 95% CI, 0.43–0.73).
Grade 3 or higher adverse events were reported for 47.4% of patients in the avelumab arm and 25.2% of patients in the control arm. Most adverse events with avelumab were immune related, and 9% of patients who received avelumab were treated with high-dose glucocorticoids for these events.
A study (NCT01772004) of avelumab (10 mg/kg IV every 14 days) included 249 patients with metastatic urothelial carcinoma who had progressed after treatment with platinum-based chemotherapy.[63,64][Level of evidence C3]
Sources: NCT01772004 · 63 · 64 · Level of evidence C3
A study (NCT01772004) of avelumab (10 mg/kg IV every 14 days) included 249 patients with metastatic urothelial carcinoma who had progressed after treatment with platinum-based chemotherapy.[63,64][Level of evidence C3]
Among the 161 patients with at least 6 months of follow-up, the overall response rate was 17%, and response was ongoing in 23 of 28 responders with a median follow-up of 7.3 months. Six percent of the patients had a complete response.
The overall response rate was 25.0% in patients with PD-L1 expression of at least 5% and 14.7% for those with less than 5% PD-L1 positivity.
Median PFS was 6.3 weeks; 23% of the patients were progression free at 24 weeks.
A treatment-related adverse event was reported in 66.7% of patients, including 8.4% of patients with high-grade adverse events. There was one treatment-related death from pneumonitis. High-grade immune-related adverse events were reported in 2.4% of patients.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Durvalumab is an anti–PD-L1 monoclonal antibody with activity when given perioperatively with neoadjuvant chemotherapy in patients with resectable disease. However, durvalumab was voluntarily withdrawn in 2021 as a first-line therapy for locally advanced or metastatic urothelial cancer. The withdrawal was based on the randomized DANUBE trial (NCT02516241) which showed no significant improvement in OS.[65][Level of evidence A1]
Sources: DANUBE · 65 · Level of evidence A1
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Definitive radiation therapy with or without concurrent chemotherapy, evaluated mainly in patients with locally advanced (T2–T4) disease, appears to have minimal curative potential in patients with regional lymph node metastases.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Urinary diversion may be indicated, not only for palliation of urinary symptoms, but also for preservation of renal function in candidates for chemotherapy.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
The prognosis for any patient with progressive or recurrent invasive bladder cancer is generally poor. Management of recurrence depends on previous therapy, sites of recurrence, and individual patient considerations.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Treatment options for patients with recurrent bladder cancer include:
Combination chemotherapy.
Sources: Combination chemotherapy
Immunotherapy.
Sources: Immunotherapy
Targeted therapy.
Sources: Targeted therapy
Surgery for new superficial or localized tumors.
Sources: Surgery
Palliative therapy.
Sources: Palliative therapy
Clinical trials.
Sources: Clinical trials
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Patients who have not received previous chemotherapy for urothelial carcinoma should consider chemotherapy as described above for stage IV disease.
Sources: stage IV disease
In patients with recurrent transitional cell carcinoma, combination chemotherapy has produced high response rates, with occasional complete responses seen.[1,2]
Cisplatin-based combination chemotherapy regimens are the standard of care for first-line therapy for stage IV bladder cancer in patients who can tolerate it.[3-7] The only chemotherapy regimens that have been shown to result in longer survival in randomized controlled trials are MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin), dose-dense MVAC, and CMV (cisplatin, methotrexate, and vinblastine).
GC (gemcitabine and cisplatin) was compared with MVAC in a randomized controlled trial, and neither regimen was associated with a statistically significant difference in response rate or survival. The two regimens are generally considered equivalent, but they have never been compared in a noninferiority trial. Of note, patients with good performance status and lymph node–only disease have a low but significant rate of achieving a durable complete remission with MVAC or GC. For example, in a large, randomized controlled trial comparing MVAC with GC, the 5-year overall survival (OS) rate was 20.9% in patients with lymph node–only disease.[8] Dose-dense MVAC and standard-dose MVAC were compared in a randomized controlled trial, and dose-dense MVAC was associated with longer survival.
Sources: 8
Single-agent cisplatin and multiagent regimens that do not include cisplatin have never resulted in improved survival in a randomized controlled trial. For patients who are not candidates for cisplatin-based multiagent chemotherapy regimens, there is no regimen that has been shown to prolong survival. However, many regimens have demonstrated radiologically measurable responses.
These regimens include carboplatin plus paclitaxel,[9] carboplatin plus gemcitabine,[10-12] paclitaxel plus gemcitabine,[13-15] single-agent gemcitabine,[16,17] and single-agent paclitaxel.[18-20] The regimens of carboplatin, methotrexate, and vinblastine; carboplatin, epirubicin, methotrexate, and vinblastine; and paclitaxel, gemcitabine, and carboplatin have been studied but are not widely used.[21-24]
Sources: 9 · 10 · 12 · 13 · 15 · 16 · 17 · 18 · 20 · 21 · 24
Evidence (combination chemotherapy):
In a prospective randomized trial that compared MVAC with cisplatin, cyclophosphamide, and doxorubicin, the MVAC regimen demonstrated improved response rate and longer median survival (48 weeks vs. 36 weeks; P = .003).[25]
Sources: 25
Results from a randomized trial that compared MVAC with single-agent cisplatin in advanced bladder cancer also showed a significant advantage with MVAC in both response rate and median survival (12.5 months vs. 8.2 months; P = .002).[26]
Sources: 26
A multicenter randomized controlled trial compared CMV with methotrexate plus vinblastine without cisplatin in 214 patients.[27]
Sources: 27
A multicenter randomized controlled trial compared CMV with methotrexate plus vinblastine without cisplatin in 214 patients.[27]
The relative risk of dying was 0.68 (95% confidence interval [CI], 0.51–0.90; P = .0065) in favor of CMV.
The median survival was 7 months with CMV compared with 4.5 months for methotrexate plus vinblastine.
The European Organisation for Research and Treatment of Cancer (EORTC) conducted a randomized trial that included 263 patients with advanced bladder cancer. The study evaluated the efficacy of a high-dose intensity MVAC regimen given every 2 weeks with granulocyte colony-stimulating factor (G-CSF) versus a classic MVAC regimen given every 4 weeks.[28]
Sources: 28
The European Organisation for Research and Treatment of Cancer (EORTC) conducted a randomized trial that included 263 patients with advanced bladder cancer. The study evaluated the efficacy of a high-dose intensity MVAC regimen given every 2 weeks with granulocyte colony-stimulating factor (G-CSF) versus a classic MVAC regimen given every 4 weeks.[28]
Although there was no significant difference in OS at a median follow-up of 3.2 years (hazard ratio [HR], 0.80; 95% CI, 0.60–1.06; P = .122), an update at a median follow-up of 7.3 years reported that the high-dose intensity MVAC regimen was associated with improved OS (HR, 0.76; 95% CI, 0.58–0.99; P = .042), with a 5-year survival rate of 22% compared with 14% in patients treated with the classic MVAC regimen.
The high-dose intensity MVAC regimen was also associated with higher response rates (72% vs. 58%; P = .016), improved median progression-free survival (PFS) (9.5 months vs. 8.1 months; P = .017), and decreased neutropenic fever (10% vs. 26%; P < .001), although only 19% of patients treated with a classic MVAC regimen ever received G-CSF.[28][Level of evidence A1] An imbalance in baseline prognostic factors (i.e., visceral metastases were found in 37 patients randomly assigned to the high-dose MVAC regimen and 47 patients assigned to the classic MVAC regimen) may account, in part, for these results.
Sources: 28 · Level of evidence A1
A multicenter, randomized, phase III trial compared GC with MVAC in 405 patients with advanced or metastatic bladder cancer.Although this study was not designed to show the equivalence of the two regimens, the similar efficacy and reduced toxic effects of GC make it a reasonable alternative in patients who may not tolerate the MVAC regimen.
A multicenter, randomized, phase III trial compared GC with MVAC in 405 patients with advanced or metastatic bladder cancer.Although this study was not designed to show the equivalence of the two regimens, the similar efficacy and reduced toxic effects of GC make it a reasonable alternative in patients who may not tolerate the MVAC regimen.
GC yielded response rates, time-to-progression, and OS (HR, 1.04; 95% CI, 0.82–1.32; P = .75) similar to MVAC, but GC had a better safety profile and was better tolerated than MVAC.[29][Level of evidence A1]
Sources: 29 · Level of evidence A1
Other chemotherapy regimens that have shown activity in metastatic bladder cancer include single-agent paclitaxel, single-agent gemcitabine, single-agent pemetrexed, carboplatin combined with either gemcitabine or paclitaxel, and gemcitabine combined with paclitaxel. There are no phase III trials demonstrating a survival or quality-of-life benefit from second-line chemotherapy.[30-37]
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Immunotherapy has emerged as a treatment alternative for patients with recurrent bladder cancer. Anti−programmed death-1 (PD-1) or anti−programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors have activity against urothelial carcinoma in patients who have previously been treated with, or who are ineligible for, cisplatin-based chemotherapy.[38-42] There are several approved agents. However, pembrolizumab has the most robust data in terms of level of evidence and survival.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Pembrolizumab is a humanized monoclonal antibody that binds to PD-1. In patients previously treated with platinum-based chemotherapy, pembrolizumab has prolonged OS compared with second-line chemotherapy. As a result, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma who fall into one of the following three categories:
Cisplatin-ineligible and have tumors that express PD-L1 (combined positive score [CPS] of at least 10).
Cisplatin- and carboplatin-ineligible.
Progression of disease after treatment with platinum-based chemotherapy.
Evidence (pembrolizumab):
An open-label, international, phase III, randomized controlled trial (NCT02256436) included patients whose disease had progressed after treatment with platinum-based chemotherapy. Patients received pembrolizumab (200 mg intravenously [IV] every 21 days) or second-line chemotherapy (investigator’s choice of paclitaxel, docetaxel, or vinflunine).[43]
Sources: NCT02256436 · 43
An open-label, international, phase III, randomized controlled trial (NCT02256436) included patients whose disease had progressed after treatment with platinum-based chemotherapy. Patients received pembrolizumab (200 mg intravenously [IV] every 21 days) or second-line chemotherapy (investigator’s choice of paclitaxel, docetaxel, or vinflunine).[43]
The median OS was longer with pembrolizumab (10.3 months vs.7.4 months; HR, 0.73; 95% CI, 0.59–0.91).
In patients with a PD-L1 CPS of at least 10, median OS was 8.0 months with pembrolizumab compared with 5.2 months of chemotherapy (HR, 0.57; 95% CI, 0.37–0.88).
The PFS rate at 12 months was 16.8% (95% CI, 12.3%–22.0%) in the pembrolizumab arm and 6.2% (95% CI, 3.3%–10.2%) in the chemotherapy arm.
The objective response rate was 21.1% in the pembrolizumab arm and 11.4% in the chemotherapy arm. Among those who responded, the median duration of response was longer than 18 months with pembrolizumab compared with a response of 4.3 months with chemotherapy.
Pembrolizumab was associated with a lower rate of treatment-related adverse events than chemotherapy (60.9% vs. 90.2%) and a lower rate of high-grade adverse events (15.0% vs. 49.4%). The most common adverse events with pembrolizumab were pruritus, fatigue, nausea, diarrhea, and decreased appetite.[43][Level of evidence A1]
Sources: 43 · Level of evidence A1
A single-arm phase II trial (NCT02335424) of pembrolizumab included 370 treatment-naïve, cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.[44]
Sources: NCT02335424 · 44
A single-arm phase II trial (NCT02335424) of pembrolizumab included 370 treatment-naïve, cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.[44]
The overall response rate was 29%. In patients with a PD-L1 CPS of at least 10, the overall response rate was 51%.
The median duration of response had not been reached. Eighty-two percent of responses lasted at least 6 months.
Ten percent of patients had a serious treatment-related adverse event, and one patient died of treatment-related adverse events. The most common high-grade adverse events were fatigue (2%), elevated alkaline phosphatase (1%), colitis (1%), and muscle weakness (1%).[44][Level of evidence C3]
Sources: 44 · Level of evidence C3
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Atezolizumab is a humanized monoclonal antibody that binds to PD-L1 and prevents it from binding to its receptors PD-1 or B7-1. Atezolizumab was voluntarily withdrawn in 2022 as a first-line treatment option for locally advanced or metastatic urothelial cancer. The withdrawal was based on the results of the randomized IMvigor130 trial (NCT02807636) which showed no significant difference in OS.[45][Level of evidence A1]; [46][Level of evidence A1] Atezolizumab has been studied as a second-line therapy after platinum-based chemotherapy.
Sources: IMvigor130 · 45 · Level of evidence A1 · 46 · Level of evidence A1
Evidence (atezolizumab):
The IMvigor211 trial (NCT02302807) is a randomized controlled trial that compared atezolizumab with second-line chemotherapy (docetaxel, paclitaxel, or vinflunine) in 931 patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum-containing chemotherapy.[47] The trial design specified that OS would be primarily assessed in patients with PD-L1 expression of at least 5%.
Sources: IMvigor211 · 47
The IMvigor211 trial (NCT02302807) is a randomized controlled trial that compared atezolizumab with second-line chemotherapy (docetaxel, paclitaxel, or vinflunine) in 931 patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum-containing chemotherapy.[47] The trial design specified that OS would be primarily assessed in patients with PD-L1 expression of at least 5%.
The median OS was 11.1 months for atezolizumab versus 10.6 months for chemotherapy in patients with PD-L1 expression of at least 5% (P = .41).[47][Level of evidence A1]
Sources: 47 · Level of evidence A1
Response rates were also similar: 23% with atezolizumab and 22% with chemotherapy.
Patients receiving atezolizumab had a lower rate of high-grade toxicity (20% vs. 43%) and a lower rate of treatment discontinuation resulting from adverse events (7% vs. 18%).
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Nivolumab is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody that blocks interaction between PD-L1 and PD-L2 with PD-1. There are no published controlled trials and thus no data regarding whether nivolumab results in longer survival or improved quality of life.
Evidence (nivolumab):
A multicenter trial (NCT01928394) included 86 patients with metastatic urothelial carcinoma whose disease progressed after platinum-based chemotherapy. Patients received nivolumab (3 mg/kg IV every 2 weeks).[40][Level of evidence B4]
Sources: NCT01928394 · 40 · Level of evidence B4
A multicenter trial (NCT01928394) included 86 patients with metastatic urothelial carcinoma whose disease progressed after platinum-based chemotherapy. Patients received nivolumab (3 mg/kg IV every 2 weeks).[40][Level of evidence B4]
With a minimum follow-up of 9 months and a median follow-up of 15 months, 24% had an objective response, and 22% had grade 3 or 4 adverse events.
The most common adverse events were elevated lipase or amylase, fatigue, rash, dyspnea, lymphopenia, and neutropenia.
Another multicenter study (NCT02387996) of 270 patients with locally advanced or metastatic urothelial carcinoma that had progressed after treatment with platinum-based chemotherapy reported an objective response rate of 20%.[39][Level of evidence B4]
Sources: NCT02387996 · 39 · Level of evidence B4
Another multicenter study (NCT02387996) of 270 patients with locally advanced or metastatic urothelial carcinoma that had progressed after treatment with platinum-based chemotherapy reported an objective response rate of 20%.[39][Level of evidence B4]
When evaluated by PD-L1 expression, the objective response rate was 28% in those with PD-L1 expression of 5% or greater; 24% in those with PD-L1 expression of 1% or greater; and 16% in those with PD-L1 expression of less than 1%.
Grade 3 to 4 adverse events were reported in 18% of patients.
There were three treatment-related deaths.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Avelumab is a monoclonal anti–PD-L1 antibody that has shown activity against urothelial carcinoma. A randomized controlled trial reported an OS benefit from maintenance avelumab when given after platinum-based chemotherapy in patients whose cancer did not progress during chemotherapy.
Evidence (avelumab):
A phase III study (NCT02603432) evaluated maintenance avelumab (10 mg/kg IV every 14 days) in patients with metastatic urothelial carcinoma who had not progressed during treatment with first-line chemotherapy with gemcitabine combined with either cisplatin or carboplatin. After four to six cycles of chemotherapy, 700 patients were randomly assigned to receive either best supportive care (control arm) or best supportive care plus maintenance avelumab (avelumab arm).[48][Level of evidence A1]
Sources: NCT02603432 · 48 · Level of evidence A1
A phase III study (NCT02603432) evaluated maintenance avelumab (10 mg/kg IV every 14 days) in patients with metastatic urothelial carcinoma who had not progressed during treatment with first-line chemotherapy with gemcitabine combined with either cisplatin or carboplatin. After four to six cycles of chemotherapy, 700 patients were randomly assigned to receive either best supportive care (control arm) or best supportive care plus maintenance avelumab (avelumab arm).[48][Level of evidence A1]
The 1-year OS rate was 71.3% in the avelumab arm compared with 58.4% in the control arm (HR, 0.69; 95% CI, 0.56–0.86).
The OS benefit was limited to patients whose tumors were PD-L1-positive. The OS in patients with PD-L1–negative tumors was not significantly different between the two arms.
Patients with PD-L1–positive tumors had a 1-year OS rate of 79.1% in the avelumab arm and 60.4% in the control arm (HR, 0.56; 95% CI, 0.40–0.79).
In the overall study population, the median PFS was 3.7 months for patients in the avelumab arm and 2.0 months for patients in the control arm (HR, 0.62; 95% CI, 0.52–0.75). In patients with PD-L1–positive tumors, the median PFS was 5.7 months with avelumab and 2.1 months with best supportive care alone (HR, 0.56; 95% CI, 0.43–0.73).
Grade 3 or higher adverse events were reported for 47.4% of patients in the avelumab arm and 25.2% of patients in the control arm. Most adverse events with avelumab were immune related, and 9% of patients who received avelumab were treated with high-dose glucocorticoids for these events.
A study (NCT01772004) of avelumab (10 mg/kg IV every 14 days) in 249 patients with metastatic urothelial carcinoma who had progressed after treatment with platinum-based chemotherapy reported the following results:[49,50][Level of evidence C3]
Sources: NCT01772004 · 49 · 50 · Level of evidence C3
A study (NCT01772004) of avelumab (10 mg/kg IV every 14 days) in 249 patients with metastatic urothelial carcinoma who had progressed after treatment with platinum-based chemotherapy reported the following results:[49,50][Level of evidence C3]
Among the 161 patients with at least 6 months of follow-up, the overall response rate was 17%, and response was ongoing in 23 of 28 responders with a median follow-up of 7.3 months. Six percent of the patients had a complete response.
The overall response rate was 25.0% in patients with PD-L1 expression of at least 5% and 14.7% for those with PD-L1 expression of less than 5%.
The median progression-free survival was 6.3 weeks; 23% of the patients were progression free at 24 weeks.
A treatment-related adverse event was reported in 66.7% of patients, including 8.4% of patients with high-grade adverse events. There was one treatment-related death from pneumonitis. High-grade immune-related adverse events were reported in 2.4% of patients.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Durvalumab is an anti–PD-L1 monoclonal antibody with activity when given perioperatively with neoadjuvant chemotherapy in patients with resectable disease. However, durvalumab was voluntarily withdrawn in 2021 as a first-line therapy for locally advanced or metastatic urothelial cancer. The withdrawal was based on the randomized DANUBE trial (NCT02516241) which showed no significant improvement in OS.[51][Level of evidence A1]
Sources: DANUBE · 51 · Level of evidence A1
Durvalumab was assessed as second-line therapy after platinum-based chemotherapy or for cisplatin-eligible patients.
Evidence (durvalumab):
The efficacy of durvalumab (10 mg/kg IV every 14 days) was assessed in a study (NCT01693562) of 191 patients with locally advanced or metastatic urothelial carcinoma whose disease had progressed while they were on chemotherapy or who were either ineligible for or unwilling to be treated with chemotherapy.[52][Level of evidence C3]
Sources: NCT01693562 · 52 · Level of evidence C3
The efficacy of durvalumab (10 mg/kg IV every 14 days) was assessed in a study (NCT01693562) of 191 patients with locally advanced or metastatic urothelial carcinoma whose disease had progressed while they were on chemotherapy or who were either ineligible for or unwilling to be treated with chemotherapy.[52][Level of evidence C3]
With a median follow-up of 5.78 months, the overall response rate was 17.8%.
The response rate was 27.6% in patients with high expression of PD-L1 compared with 5.1% in patients with low or no PD-L1 expression.
High-grade adverse events were reported in 6.8% of patients, including 2.1% with high-grade immune-mediated adverse events.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Ramucirumab is an immunoglobulin G1 monoclonal antibody that blocks the vascular endothelial growth factor receptor-2 (VEGFR-2). The FDA approved ramucirumab for patients with gastric carcinoma and gastroesophageal junction adenocarcinoma, but not for patients with bladder cancer.
Evidence (ramucirumab):
Docetaxel chemotherapy plus ramucirumab was compared with docetaxel plus placebo in a double-blind, multicenter, randomized controlled phase III trial in 530 patients with metastatic urothelial carcinoma that had progressed after treatment with platinum-based chemotherapy. Forty-five patients (8.5%) had previously been treated with immunotherapy.[53][Level of evidence B1]
Sources: 53 · Level of evidence B1
Docetaxel chemotherapy plus ramucirumab was compared with docetaxel plus placebo in a double-blind, multicenter, randomized controlled phase III trial in 530 patients with metastatic urothelial carcinoma that had progressed after treatment with platinum-based chemotherapy. Forty-five patients (8.5%) had previously been treated with immunotherapy.[53][Level of evidence B1]
OS was not significantly different between the two arms.
The median PFS was 1.3 months (39 days) longer in the ramucirumab arm compared with the placebo arm (4.1 months vs. 2.8 months; HR, 0.696; 95% CI, 0.573–0.845, P = .0002).
The overall response rate was 26% in the ramucirumab arm and 14% in the placebo arm.
Treatment was discontinued because of adverse events in 19% of patients who received docetaxel plus ramucirumab and 8% of patients who received docetaxel plus placebo.
Grade 3 or higher adverse events were reported in 48% of patients in the ramucirumab arm and 41% of patients in the placebo arm. Adverse events included febrile neutropenia, epistaxis, hypertension, hematuria, and proteinuria. Sepsis occurred in 2% of patients who received ramucirumab, and no patients who received placebo.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Enfortumab vedotin is a type of targeted therapy called an antibody-drug conjugate. Antibody-drug conjugates consist of a monoclonal antibody chemically linked to a drug. The monoclonal antibody part of enfortumab vedotin binds to a protein called nectin-4, which is found on the surface of most bladder cancer cells. The antibody is chemically linked to monomethyl auristatin E, or MMAE, a type of chemotherapy drug called a microtubule inhibitor. Once the conjugate is taken up by cells, the drug stops them from dividing and leads to their death.
The FDA approved enfortumab vedotin for patients with metastatic urothelial carcinoma that has progressed after treatment with both platinum-based first-line chemotherapy and second-line therapy with an immune checkpoint inhibitor. The approval was based on a single-arm trial of 125 patients with metastatic urothelial carcinoma.[54]
Sources: 54
Evidence (enfortumab vedotin):
In a single-arm trial, 125 patients with metastatic urothelial carcinoma were treated with enfortumab vedotin.[54]Because there was no control arm, this study could not demonstrate an improvement in OS or quality of life. A follow-up phase III trial is under way to assess the benefits of this medication.
Sources: 54
In a single-arm trial, 125 patients with metastatic urothelial carcinoma were treated with enfortumab vedotin.[54]Because there was no control arm, this study could not demonstrate an improvement in OS or quality of life. A follow-up phase III trial is under way to assess the benefits of this medication.
There was a 44% overall response rate and a 12% complete response rate.
The median duration of response was 7.6 months.
Adverse events included fatigue (50%), peripheral neuropathy (50%), alopecia (49%), rash (48%), decreased appetite (44%), and dysgeusia (40%).
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Erdafitinib (JNJ-42756493) is a potent FGFR 1–4 tyrosine kinase inhibitor. The FDA approved erdafitinib for patients with urothelial carcinoma and a variant in one of the four FGFR genes and disease that has progressed after prior chemotherapy.
Roughly 20% of metastatic urothelial carcinomas of the bladder have FGFR variants, as do 35% of urothelial carcinomas of the ureters and renal pelvis.
Evidence (erdafitinib):
A phase II trial included patients with metastatic urothelial carcinoma whose disease had progressed during or after systemic chemotherapy.[55] To be eligible for the study, patients were required to have tumors with an FGFR3 variant or an FGFR2::FGFR3 gene fusion. The trial was originally designed as a randomized phase II trial comparing continuous with intermittent treatment, but after an interim safety analysis, the trial was converted to a single-arm study of continuous treatment with dose escalation. The published analysis focuses on this latter phase of the study, referred to as the “selected-regimen group.” The selected-regimen group consisted of 99 patients, 74 with an FGFR3 variant and 25 with an FGFR2::FGFR3 gene fusion.
Sources: 55
A phase II trial included patients with metastatic urothelial carcinoma whose disease had progressed during or after systemic chemotherapy.[55] To be eligible for the study, patients were required to have tumors with an FGFR3 variant or an FGFR2::FGFR3 gene fusion. The trial was originally designed as a randomized phase II trial comparing continuous with intermittent treatment, but after an interim safety analysis, the trial was converted to a single-arm study of continuous treatment with dose escalation. The published analysis focuses on this latter phase of the study, referred to as the “selected-regimen group.” The selected-regimen group consisted of 99 patients, 74 with an FGFR3 variant and 25 with an FGFR2::FGFR3 gene fusion.
The response rate by independent radiological review was 34%.
The response rate was higher among the patients with FGFR3 variants than among the patients with FGFR2::FGFR3 gene fusions.
Grade 3 adverse events that affected at least 10% of patients included stomatitis and hyponatremia. The most common adverse events of any grade were hypophosphatemia (77%), stomatitis (58%), diarrhea (51%), dry mouth (46%), decreased appetite (38%), and dysgeusia (37%).
A randomized controlled trial (THOR [NCT03390504]) included 266 patients with locally advanced or metastatic urothelial carcinoma who had received anti–PD-1 or anti–PD-L1 therapy. Patients had FGFR2 or FGFR3 pathogenic variants or gene fusions. The study compared erdafitinib with chemotherapy.[56][Level of evidence A1]
Sources: THOR · 56 · Level of evidence A1
A randomized controlled trial (THOR [NCT03390504]) included 266 patients with locally advanced or metastatic urothelial carcinoma who had received anti–PD-1 or anti–PD-L1 therapy. Patients had FGFR2 or FGFR3 pathogenic variants or gene fusions. The study compared erdafitinib with chemotherapy.[56][Level of evidence A1]
At a median follow-up of 15.9 months, the OS was 12.1 months in the erdafitinib arm and 7.8 months in the chemotherapy arm (HR, 0.64; 95% CI, 0.47–0.88).
The median PFS was 5.6 months in the erdafitinib arm and 2.7 months in the chemotherapy arm (HR, 0.58; 95% CI, 0.44–0.78).
Grade 3 or higher treatment-related adverse events occurred in 45.9% of patients in the erdafitinib arm and 46.4% of patients in the chemotherapy arm. The most common grade 3 or higher events were hand-foot syndrome (9.6%), stomatitis (8.1%), onycholysis (5.9%), and hyperphosphatemia (5.2%) in the erdafitinib arm and neutropenia (14.3%) in the chemotherapy arm.
Erdafitinib caused central serous retinopathy (CSR) of any grade in 17.0% of patients. CSR was grade 3 or higher in 2.2% of patients, which is consistent with prior safety data. Monthly ophthalmological examinations are recommended for the first 4 months of treatment and then every 3 months thereafter, as CSR may necessitate dose interruptions, dose reductions, and, sometimes, permanent erdafitinib discontinuation.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
For information about the treatment of new superficial or locally invasive tumors that develop in patients who received previous conservative therapy for superficial bladder neoplasia, see the Treatment Options for Stage I Bladder Cancer section.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Patients with symptomatic tumors should consider palliative radiation therapy.
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025. Captured 2026-09-09.
Recurrent or progressive disease in distant sites or after definitive local therapy has an extremely poor prognosis, and patients should consider clinical trials whenever possible.
Source: Bladder Cancer Treatment, National Cancer Institute.
Source updated: September 12, 2024. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Bladder cancer is sometimes treated with external beam radiation therapy. This type of radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Radiation therapy may be given alone or with other types of treatment, such as chemotherapy.
Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.
Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects
Source: Bladder Cancer Treatment, National Cancer Institute.
Source updated: September 12, 2024. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemotherapy may be given alone or with other types of treatment. The way the chemotherapy is given depends on the type and stage of the cancer being treated.
Source: Bladder Cancer Treatment, National Cancer Institute.
Source updated: September 12, 2024. Captured 2026-09-09.
Systemic chemotherapy for bladder cancer is when chemotherapy drugs are injected into a vein. When given this way, the drugs enter the bloodstream to reach cancer cells throughout the body. Systemic chemotherapy drugs that may be used to treat bladder cancer are:
Sources: injected
carboplatin
Sources: carboplatin
cisplatin
Sources: cisplatin
doxorubicin
Sources: doxorubicin
fluorouracil (5-FU)
Sources: fluorouracil
gemcitabine
Sources: gemcitabine
methotrexate
Sources: methotrexate
mitomycin
Sources: mitomycin
paclitaxel
Sources: paclitaxel
vinblastine
Sources: vinblastine
Combinations of these drugs may be used. Other chemotherapy drugs not listed here may also be used.
Source: Bladder Cancer Treatment, National Cancer Institute.
Source updated: September 12, 2024. Captured 2026-09-09.
For bladder cancer, chemotherapy may be intravesical, meaning it is put into the bladder through a tube inserted into the urethra. Intravesical treatments flush the bladder with drugs that kill cancer cells that remain after surgery. This lowers the chance of the cancer coming back.
Mitomycin and gemcitabine are two chemotherapy drugs given as intravesical chemotherapy to treat bladder cancer. These drugs can also be given systemically.
To learn more about how chemotherapy works, how it is given, common side effects, and more, visit Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.
Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer
Source: Bladder Cancer Treatment, National Cancer Institute.
Source updated: September 12, 2024. Captured 2026-09-09.
Immunotherapy helps a person's immune system fight cancer. Your doctor may suggest biomarker tests to help predict your response to certain immunotherapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Sources: biomarker tests · Biomarker Testing for Cancer Treatment
Source: Bladder Cancer Treatment, National Cancer Institute.
Source updated: September 12, 2024. Captured 2026-09-09.
Systemic immunotherapy drugs used to treat urothelial cancer (a type of bladder cancer) include:
atezolizumab
Sources: atezolizumab
avelumab
Sources: avelumab
nivolumab
Sources: nivolumab
pembrolizumab
Sources: pembrolizumab
These drugs work in more than one way to kill cancer cells. They are also considered targeted therapy because they target specific changes or substances in cancer cells (visit the section on Targeted therapy).
Sources: targeted therapy · Targeted therapy
Source: Bladder Cancer Treatment, National Cancer Institute.
Source updated: September 12, 2024. Captured 2026-09-09.
BCG (bacillus Calmette-Guérin), nadofaragene firadenovec-vncg, and nogapendekin alfa inbakicept-pmln are intravesical immunotherapy drugs used to treat bladder cancer. They are given in a solution that is placed directly into the bladder using a catheter (thin tube). Intravesical treatments flush the bladder with drugs that kill cancer cells that remain after surgery. This lowers the chance of the cancer coming back.
Sources: BCG (bacillus Calmette-Guérin) · nadofaragene firadenovec-vncg · nogapendekin alfa inbakicept-pmln
Learn more about Immunotherapy to Treat Cancer and Immunotherapy Side Effects.
Sources: Immunotherapy to Treat Cancer · Immunotherapy Side Effects
Source: Bladder Cancer Treatment, National Cancer Institute.
Source updated: September 12, 2024. Captured 2026-09-09.
Targeted therapy uses drugs or other substances to block the action of specific enzymes, proteins, or other molecules involved in the growth and spread of cancer cells. Your doctor may suggest biomarker tests to help predict your response to certain targeted therapy drugs. Learn more about Biomarker Testing for Cancer.
Sources: enzymes · Biomarker Testing for Cancer
Targeted therapies used to treat bladder cancer include:
enfortumab vedotin
Sources: enfortumab vedotin
erdafitinib
Sources: erdafitinib
ramucirumab
Sources: ramucirumab
sacituzumab govitecan-hziy
Sources: sacituzumab govitecan-hziy
Learn more about Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Advanced Solid Tumors
ClinicalTrials.gov recordSolid Tumors
ClinicalTrials.gov recordAdvanced or Metastatic Solid Tumors
ClinicalTrials.gov recordOvary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer(NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
ClinicalTrials.gov recordBladder Cancer
ClinicalTrials.gov recordUrothelial Cancer
ClinicalTrials.gov recordBladder Cancer
ClinicalTrials.gov recordUrothelial Cancer
ClinicalTrials.gov recordUrothelial Cancer
ClinicalTrials.gov recordVarious Advanced Cancer
ClinicalTrials.gov recordUrothelial Cancer
ClinicalTrials.gov recordOvary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer (NSCLC)
ClinicalTrials.gov recordUrothelial Cancer
ClinicalTrials.gov recordBladder Cancer
ClinicalTrials.gov recordVarious Advanced Cancer
ClinicalTrials.gov recordSuperficial Bladder Cancer
ClinicalTrials.gov recordUrothelial Carcinoma
ClinicalTrials.gov recordUrothelial Carcinoma Associated 1 RNA, Human
ClinicalTrials.gov recordBladder Cancer
ClinicalTrials.gov recordUrothelial Cancer
ClinicalTrials.gov recordMetastatic Urothelial Cancer
ClinicalTrials.gov recordLocalized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Locally...
ClinicalTrials.gov recordUrothelial Cancer
ClinicalTrials.gov recordUreteral Cancer, Urothelial Cancer, Bladder Cancer
ClinicalTrials.gov recordNon-muscle-invasive Bladder Cancer
ClinicalTrials.gov recordMuscle Invasive Bladder Cancer
ClinicalTrials.gov recordUrinary Bladder Cancer, Muscle-invasive
ClinicalTrials.gov recordUrothelial Cancer
ClinicalTrials.gov recordUrinary Bladder Neoplasms
ClinicalTrials.gov recordMuscle-invasive Bladder Cancer
ClinicalTrials.gov recordBladder Cancer
ClinicalTrials.gov recordMetastatic Urothelial Cancer
ClinicalTrials.gov recordBladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
ClinicalTrials.gov recordBladder Cancer, Transitional Cell Bladder Cancer, Urethra Cancer, Ureter Cancer, Renal Pelvis Cancer
ClinicalTrials.gov recordRecurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage 0a...
ClinicalTrials.gov recordBladder Cancer
ClinicalTrials.gov recordUrothelial Carcinoma
ClinicalTrials.gov recordDistal Urethral Cancer, Proximal Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage II Bladder Cancer, Stage III Bladder Cancer, Urethral Cancer Associated With...
ClinicalTrials.gov recordUrothelial Carcinoma, Urethral Neoplasms, Urinary Bladder Neoplasms, Kidney Neoplasms
ClinicalTrials.gov recordDistal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder...
ClinicalTrials.gov recordBladder Cancer, Carcinoma, Transitional Cell, Renal Pelvis Cancer, Ureter Cancer, Urethra Cancer
ClinicalTrials.gov recordUrothelial Carcinoma
ClinicalTrials.gov recordUrinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms
ClinicalTrials.gov recordBladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive...
ClinicalTrials.gov recordAdvanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic...
ClinicalTrials.gov recordBladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage II...
ClinicalTrials.gov recordLocally Advanced or Metastatic Urothelial Carcinoma
ClinicalTrials.gov record1 INDICATIONS AND USAGE BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at...
Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has:susceptible FGFR3 or FGFR2 genetic alterations, andprogressed during or following at least one line of prior platinum-containing...
( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy.
Locally advanced or metastatic urothelial carcinoma following diease progression on platinum-containing chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
Previously-treated Urothelial Carcinoma BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who: Have disease progression during or following platinum-containing chemotherapy...
Bladder Cancer
1.3 Advanced Bladder Cancer Cisplatin for injection is indicated for the treatment of advanced bladder cancer.
Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
• IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with muscle invasive...
KEYTRUDA QLEX, in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
KEYTRUDA QLEX, as a single agent, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemotherapy, or who have disease progression...
KEYTRUDA, in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
Locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy 1
KEYTRUDA, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or...
Surgery for new superficial or localized tumors
1.8 Urothelial Carcinoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.
OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:
Locally advanced or metastatic urothelial carcinoma that: • progressed during or following platinum-containing chemotherapy • progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy
OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
1.10 Urothelial Carcinoma OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [see Clinical Studies (14.10) ] .
• in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle invasive bladder...
Treatment of Recurrent Bladder Cancer
Radical cystectomy (in rare, highly selected patients with extensive or refractory superficial high-grade tumors)
Treatment of Stage 0 Bladder Cancer
Treatment of Stage I Bladder Cancer
Treatment of Stage IV Bladder Cancer
1.6 Muscle Invasive Bladder Cancer TECENTRIQ HYBREZA, as monotherapy, is indicated as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual...
1.6 Muscle Invasive Bladder Cancer TECENTRIQ, as a single agent, is indicated as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease...
Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
Patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 as determined by an FDA approved test or who are not eligible for any...
Urothelial Carcinoma
1 INDICATIONS AND USAGE ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors....
DailyMed labelANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors....
DailyMed labelBALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior...
DailyMed labelCisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer ( 1.1 ) • Advanced ovarian cancer ( 1.2 ) • Advanced bladder cancer ( 1.3 ) 1.1 Advanced Testicular Cancer Cisplatin for...
DailyMed labelINDICATIONS Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors...
DailyMed labelCYSVIEW is indicated for the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), in adult patients: With suspected or known lesion(s) based on a prior cystoscopy Undergoing surveillance cystoscopy for...
DailyMed labelINLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. INLEXZO is a...
DailyMed labelJELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). JELMYTO is an alkylating drug indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer...
DailyMed labelPADCEV ® , in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with...
DailyMed labelVALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable...
DailyMed labelZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI is an alkylating drug indicated for the treatment of adult patients with...
DailyMed label